PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 1A PHASE 2/3, RANDOMIZED, DOUBLE -BLIND, D OUBLE -DUMMY, 
PLACEBO -CONTROLLED S TUDY TO EVALUATE THE SAFETY AND 
EFFICACY OF 2 REGIME NS OF ORALLY ADMINIS TERED 
PF-07321332/RITONAVI R IN PREVENTING SYMPTOMAT IC SARS -COV -2 
INFECTION IN ADULT H OUSEHOLD CONTACTS OF AN INDIVIDUAL WITH 
SYMPTOMATIC COVID- 19
Study Intervention Number: PF-07321332
Study Intervention Name: [CONTACT_336280]: [ADDRESS_1068966] Number: 2021- 002894- 24
ClinicalTrials.gov ID:  [STUDY_ID_REMOVED]
Protocol Number: C4671006
Phase: 2/3
Brief Title: A Phase 2/3 Postexposure Prophylaxis Study of PF -07321332/Ritonavir 
in Adult Household Contacts of an Individual With Symptomatic COVID -19
This document and accom panying materials contain confidential information belonging to [COMPANY_007]. Except 
as otherwise agreed to in w riting, by [CONTACT_22788], you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289] ) 
or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.

PF-[ADDRESS_1068967] of country  health authorities and IRBs/ECs and any  protocol administrative 
clarification letter.
Amendment 2 ( 25-January - 2022)
Overall Rationale for the Amendment: 
Considering the high anti -SARS -CoV -2 antibody  seropositivity  rate observed in 
Study C4671006 participants recruited to date, the lower -than
-expected event rate 
(symptomatic SARS -CoV -2 infection confirmed by [CONTACT_937]-PCR), efficacy  data from 
Study C4671005, and emerging data on the Omicron variant of the SARS -CoV -2 virus, this 
amendment includes updates to the definition for the primary endpoint events, the timing of 
the interim anal ysis and associated statistica l considerations, assumptions for sample size 
estimation, and a provision to permit enrollment of previousl y vaccinated participants.   
Section # and Name [CONTACT_19523] 1.1 Synopsis
Section 3. 
OBJECTIVES, 
ENDPOINTS, and 
ESTIMANDS
Section 9.1.
Section 9.1.1. Estimands
Section [IP_ADDRESS]
Section 9.1.2. 
Multiplicity Adj ustment
Section 9.3.1. General 
ConsiderationsPrimary objective, endpoint, and 
estimand updated to include rapid 
antigen test -confirmed SARS -CoV -
2 infection.
Updated the secondary objective 
and secondary endpoint to assess 
viral titers in participants with a 
positive RT -PCR result at baseline.Updated to reduce the possibility 
of missing a laboratory 
confirmed SARS -CoV -2 
infection (and therefore a 
potential primary endpoint 
event) possibly related to 
participant swab collect ion 
methodology.  

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 3Section # and Name [CONTACT_19523] 9.3.2. Primary 
Endpoint(s)/Estimand(s) 
Analysis
Section 9.3.3. Key 
Secondary Efficacy 
Endpoint(s)/Es timand(s) 
Analysis
Section 9.3.4. Secondary 
Endpoint(s)/Estimand(s) 
Analysis
Section 1.1. Synopsis
Section 4.1. Overall 
Design
Section 9.4. Interim 
Analyses
Section [IP_ADDRESS]. Data 
Monitoring CommitteeUpdated the timing of the 
planned interim analysis from 
45% to 70% of enrollment (ie, 
when approximately 70% of 
overall participants have 
completed the Day 14 
assessments with the minimum 
number of 24 symptomatic 
infection events).
Updated the O’Brien- Fleming 
boundary accordingly based on 
the timing of the planned interim 
analysis. To maximize the amount of 
data for the Omicron variant in 
the interim dataset.
Section 1.1. Synopsis
Section 4.1. Overall 
Design
Section 9.5. Sample Size 
DeterminationIncreased the sample size to reflect 
the adjustment of the relative risk 
reduction and the placebo event 
rate. Update d based on results in 
Study C4671005 and the relative 
risk reduction and the incidence 
of primary endpoints events 
observed in the REGEN -COV 
postexposure prophylaxis study 
and baseline seropositivity rate 
observed in the study.
Section 1.3. Schedule of 
Activities
Section 6.2.1. 
Preparation and 
DispensingAdded text to specify when study 
intervention is to be dispensed. For clarification.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 4Section # and Name [CONTACT_19523] 1.3. Schedule of 
Assessments
Section 8.2.5. 
Electrocardiograms
Section 10.7. Appendix 
7: ECG Findings of 
Potential Clinical 
ConcernSection removed as ECGs are no 
longer required per Dear 
Investigator Letter dated [ADDRESS_1068968] changes from 
the Dear Investigator Letter.
Section 1.3. Schedule of 
Activities
Section 8.2.1. Medical 
HistoryAdded note regarding prior 
documented infection and details of 
vaccination.For clarification .
Section 1.3. Schedule of 
Activities
Section [IP_ADDRESS]Specified that nasal swabs will be 
collected by [CONTACT_778401] 5, 
10, and [ADDRESS_1068969] the nasal 
swab.
Nasal swab collection was to be 
done under observation by [CONTACT_778402]- person 
visits as per PACL dated 
14December 2021.To ensure accurate collection 
of nasal swab data.
Updated to reflect changes 
from PACL.
Section 2.2. BackgroundUpdated the number of 
COVID -19 cases and deaths 
worldwide.
Added text about SARS -CoV -2 
variants of concern in relation to 
vaccine efficacy.To provide recent data .
To provide background on 
emerging variants of concern 
with respect to vaccine 
efficacy and risk for 
reinfection.
Section 2.2.2. Clinical 
OverviewAdded results from 
Study C4671005 and the 
45% interim analysis results from 
Study C4671002.To provide a brief summary of 
available clinical efficacy and 
safety data.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 5Section # and Name [CONTACT_19523] 2.3.2. Benefit 
AssessmentDescribed [ADDRESS_1068970] received EUA 
in the US and EU.
Updated benefit assessment. To describe treatment options 
for COVID -19 in patients at 
high risk of progression to 
severe COVID -19.
To support the potential 
benefit of treatment and 
postexposure prophylaxis. 
Section 5.2. Exclusion 
CriteriaUpdated Exclusion Criteria #1 to 
exclude participants with a prior 
documented infection within 
6months of the screening visit. 
Also updated Exclusion Criterion 
# 14 to exclude participants who 
received any SARS -CoV -2 
vaccine within 6 months prior to 
screening or were expected to 
receive a SARS -CoV -2 vaccine, 
or other approved, authorized, or 
investigational postexposure 
prophylaxis treatment through 
Day 38.
For Exclusion Criterion #13, 
specified that participants who 
have received app roved, 
authorized, or investigational 
anti-SARS -CoV -2 mAb, 
convalescent plasma, other drugs 
for treatment of COVID -19, or 
other anti -SARS -CoV -2 biologic 
products within 6 months of 
screening would be excluded.
Added clarification to Exclusion 
Criterion #7 to align with the 
exclusion criterion in Appendix 
11. Updated Exclusion 
Criterion #[ADDRESS_1068971] sympto matic 
infection due to the omicron 
variant wanes after several 
months. Exclusion Criterion 
#[ADDRESS_1068972] been 
previously vaccinated to be 
enrolled because they may 
benefit from postexposure 
prophylaxis.
T
o facilitate i nclusion of 
previously infected 
participants who may have 
been treated with a product 
that could confound efficacy 
assessments.
Updated Exclusion Criterion 
#[ADDRESS_1068973] changes from the 
PACL dated 13 October 2021.
Section 6.1.1. 
AdministrationCo-administration of PF -07321332 
and ritonavir should be at the same 
time, but no more than 10 minutes 
apart is acceptable.Added language to specify what 
is considered to be an acceptable 
time for co -administration of 
PF-07321332 and ritonavir.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 6Section # and Name [CONTACT_19523] 6.3.2. Blinding 
of the SponsorLanguage was added to provide 
additional information about the 
study unblinding plan.To provide additional 
information so that an unblinded 
submission team could be 
formed at the time of an interim 
analysis for preparing unblinded 
analyses and documents to 
support regulatory activities.
Section 6.8. 
Concomitant TherapyFor medications permitted during 
the study, clarified that any 
authorized or approved COVID -[ADDRESS_1068974] 
results may also confirm 
SARS -CoV -2 infection.
Section 9.2. Analysis 
SetsRemoved reference to postbaseline 
measurement in the analysis set 
definitions.Updated based on FDA 
feedback.
Appendix 12. Country 
Specific RequirementsRemoved [LOCATION_009] country -specific 
guidance.Was previously included in 
error.
Appendix 12:
Section 10.12.3. 
BulgariaAdded Bulgaria country -specific 
guidance regarding Exclusion 
Criteria #3 and #5.To incorporate country- specif ic 
changes into the global protocol
and to align with the 
26October 2021 PACL.
Appendix 12: Section 
10.12.4. UkraineAdded Ukraine country -specific 
guidance regarding nasal swab 
collection.To incorporate country- specific 
changes into the global protocol
and to align with the 
22December 2021 PACL .
Section 10.8. Appendix 
8: Prohibited 
Concomitant 
Medications That May 
Result in DDIUpdated table.
Corrections and updates to the 
list of precautionary and To align with the Emergency 
Use Authorization Fact Sheet 
for PaxlovidTM.1

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 7Section # and Name [CONTACT_778437] 29 September 2021.Updated to reflect changes 
from the PACL.
Section 10.9. Appendix 
9. Signs and Symptoms 
Consistent with COVID -
19Added fatigue (low energy or 
tiredness) to targeted symptoms for 
analysis.Was inadvertently omitted in 
the previous version.
10.[ADDRESS_1068975] OF TABLES ...................................................................................................................13
1. PROTOCOL  SUMMARY ...................................................................................................14
1.1. Sy nopsis ..................................................................................................................14
1.2. Schema ....................................................................................................................19
1.3. Schedule of Activities .............................................................................................20
2. INTRODUCTION ...............................................................................................................30
2.1. Study  Rationa le.......................................................................................................30
2.2. Background .............................................................................................................30
2.2.1. Nonclinical Studies of PF
-07321332..........................................................32
2.2.2. Clinical Overview .......................................................................................32
2.3. Ben efit/Risk Assessment .........................................................................................34
2.3.1. Risk Assessment
.........................................................................................35
2.3.2. Benefit Assessment .....................................................................................37
2.3.3. Overall Benefit/Risk Conclusion ................................................................37
3. OBJECTI VES, ENDPO INTS, AND ESTIMANDS ...........................................................37
4. STUDY DESIGN .................................................................................................................39
4.1. Overall Design .........................................................................................................39
4.2. Scientific Rationale for Study  Design .....................................................................40
4.2.1. Diversity  of Study  Population ....................................................................41
4.2.2. Choice of Contraception/Barrier Requirements .........................................41
4.2.3. Collection of Retained Research Samples ..................................................41
4.3. Justification for Dose ..............................................................................................41
4.4. End of Study  Definition ..........................................................................................42
5. STUDY POPUL ATION
................................ ................................ ................................ ......43
5.1. I nclusion Criteria .....................................................................................................43
5.2. Exclusion Criteria ....................................................................................................44
5.3. L ifesty le Considerations ..........................................................................................46
5.3.1. Contraception ..............................................................................................46
5.4. Screen Failures ........................................................................................................46
5.5. Criteria for Temporarily  Delay ing 
Enrollment/Randomization/Administration of Study  Intervention ...........................47

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 96. STUDY INTERVENTIO N(S) AND CONCOMITANT THERAPY ................................ .47
6.1. Study  Intervention(s) Administered ........................................................................47
6.1.1. Administration ............................................................................................48
6.2. Preparation, Handling, Storage, and Accountability ...............................................49
6.2.1. Preparation and Dispensing ........................................................................50
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................50
6.3.1. Allocation to Study Intervention ................................................................50
6.3.2. Blinding of the Sponsor
..............................................................................51
6.3.3. Breaking the Blind ......................................................................................51
6.4. Study  Intervention Compliance ...............................................................................51
6.5. Dose Modification ...................................................................................................52
6.6. Continued Access to Study  Intervention After the End of the Study ......................52
6.7. Treatment of Overdose
............................................................................................52
6.8. Concomitant Therapy ..............................................................................................53
6.8.1. R escue Medicine .........................................................................................54
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................54
7.1. Discontinuation of Study  Intervention ....................................................................54
7.1.1. Potential Cases of Decreased eGFR ...........................................................55
7.2. Participant Discontinuation/Withdrawal From the Study .......................................[ADDRESS_1068976] to Follow -Up...................................................................................................56
8. STUDY ASSESSMENTS AND PROC EDURES ...............................................................56
8.1. Efficacy  Assessments ..............................................................................................57
8.1.1. Participant Diary .........................................................................................57
8.1.2. Daily  Signs and S ymptoms of COVI D
-19 .................................................58
8.1.3. COVID -
19 Related Medical Visit Details................................ .................. 58
8.1.4. Ox ygen Support Details ................................ ................................ .............. 59
8.1.5. Index Case Characteristics ..........................................................................59
8.1.6. Household Characteristics ................................ ................................ .......... 60
8.1.7. PRO Assessments .......................................................................................60
[IP_ADDRESS]. WPAI .........................................................................................60

PF-07321332
Protocol C4671006Final Protocol Amendment 2, 25 January 2022
Page [IP_ADDRESS]. EQ-5D-5L Scale........................................................................60
[IP_ADDRESS]. Global Impression Questions ....................................................61
8.2. Safety Assessments .................................................................................................61
8.2.1. Medical History ..........................................................................................618.2.2. Height and Weight......................................................................................618.2.3. Targeted Physical Examinations.................................................................618.2.4. Vital Signs ..................................................................................................618.2.5. Clinical Safety La boratory Asse ssments ....................................................62
8.2.6. Pregnancy Testing ......................................................................................63
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting .................63
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......64
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety...............................................[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF...................64
8.3.2. Method of Detecting AEs and SAEs ..........................................................658.3.3. Follow-Up of AEs and SAEs......................................................................658.3.4. Regulatory Reporting Requirements for SAEs...........................................658.3.5. Environmental Exposure, Exposure During Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................65
[IP_ADDRESS]. Exposure During Pregnancy......................................................[IP_ADDRESS]. Exposure During Breastfeeding ................................................[IP_ADDRESS]. Occupational Exposure .............................................................68
8.3.6. Cardiovascular and Death Events...............................................................688.3.7. Disease-Related Events and/or Disease-Related Outcomes Not 
Qualifying as AEs or SAEs..............................................................................[ADDRESS_1068977].............................................................68
[IP_ADDRESS]. Lack of Efficacy........................................................................68
8.3.9. Medical Device Deficiencies......................................................................698.3.10. Medication Errors .....................................................................................69
8.4. Pharmacokinetics ....................................................................................................70
CCI
PF-07321332
Protocol C4671006Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 118.6. Biomarkers ..............................................................................................................71
8.6.1. Specified Gene Expression (RNA) Research .............................................718.6.2. Specified Protein Research .........................................................................718.6.3. Specified Metabolomic Research ...............................................................728.6.4. SARS-CoV-2 Assessments.........................................................................72
[IP_ADDRESS]. Rapid Antigen Assessments ......................................................[IP_ADDRESS]. Viral Load Assessments ............................................................72
8.6.5. Assessments for Other Respi[INVESTIGATOR_287693]...........................................728.6.6. Retained Research Samples for Biomarkers...............................................73
8.7. Immunogenicity Assessments .................................................................................738.8. Health Economics ...................................................................................................73
9. STATISTICAL C ONSIDERATIONS ................................................................................73
9.1. Statistical Hypotheses .............................................................................................73
9.1.1. Estimands....................................................................................................74
[IP_ADDRESS]. Primary Estimand/Co-Primary Estimands ................................[IP_ADDRESS]. Secondary Estimand..................................................................74
9.1.2. Multiplicity Ad justment..............................................................................74
9.2. Analysis Sets ...........................................................................................................759.3. Statistical Analyses .................................................................................................76
9.3.1. General Considerations...............................................................................769.3.2. Primary Endpoint(s)/Estimand(s) Analysis ................................................779.3.3. Key Secondary Efficacy Endpoint(s)/Estimand(s) Analysis......................789.3.4. Secondary Endpoint(s)/Estimand(s) Analysis ............................................78
9.3.6. Other Safety Analyses ................................................................................79
[IP_ADDRESS]. Laboratory .................................................................................[IP_ADDRESS]. Physical Examination and Vital Signs ......................................79
9.3.7. Other Analyses............................................................................................79
[IP_ADDRESS]. PK Analyses ..............................................................................79
9.4. Interim Analyses .....................................................................................................809.5. Sample Size Determination.....................................................................................80
CCI
PF-07321332
Protocol C4671006Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 1210. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................82
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............82
10.1.1. Regulatory and Ethical Considerations ....................................................82
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................82
10.1.2. Financial Disclosure .................................................................................8310.1.3. Informed Consent Process ........................................................................8310.1.4. Data Protection .........................................................................................8410.1.5. Committees Structure ...............................................................................84
[IP_ADDRESS]. Data Monitoring Committee ...................................................84
10.1.6. Dissemination of Clinical Study Data ......................................................8510.1.7. Data Qualit y Assurance ............................................................................86
10.1.8. Source Documents....................................................................................8710.1.9. Study and Site Start and Closure ..............................................................8810.1.10. Publication Policy...................................................................................8910.1.11. Sponsor’s Qualified Medical Personnel .................................................89
10.2. Appendix 2: Clinical Laboratory Tests .................................................................9110.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-Up, and Reporting .....................................................................92
10.3.1. Definition of AE .......................................................................................9210.3.2. Definition of an SAE ................................................................................9310.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs During 
the Active Collection Period............................................................................94
10.3.4. Reporting of SAEs....................................................................................98
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................99
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................9910.4.2. Female Participant Reproductive Inclusion Criteria.................................9910.4.3. Woman of Childbearing Potential ..........................................................[ZIP_CODE].4.4. Contraception Methods...........................................................................101
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments 
and Study Intervention Rechallenge Guidelines .....................................................104
CCI
PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 1310.7. Append ix 7: ECG Findings of Potential Clinical Concern (No Longer 
Applicable) ..............................................................................................................106
10.8. Appendix 8: Prohibited Concomitant Medications Tha t May  Result in DDI .....107
10.9. Appendix 9: Signs and Sy mptoms Consistent With COVI D
-19 ........................116
10.10. Appendix 10: High
-Risk Close Contact [CONTACT_778403]...........................................117
10.11. Appendix 11: Risk Factors Associated With Severe COVID -19 Illness67.......118
10.12. Appendix 12: Country  Specific Requirements ..................................................119
10.12.1. Japan .....................................................................................................119
10.12.2. Bulgaria .................................................................................................119
10.12.3. Ukraine .................................................................................................120
10.13. Appendix 13: Glossary  of Terms ......................................................................121
10.14. Appendix 14: Abbreviations .............................................................................123
10.15. Appendix 14: Protocol Amendment History .....................................................[ADDRESS_1068978] OF TABLES
Table 1. Protocol -Required Safet y Laboratory  Assessments .................................91
Table 2. Signs and Sy mptoms Consistent With COVI D
-19.................................116

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 141.PROTOCOL SUMMARY
1.1.Synopsis 
A Phase 2/3, Randomized, Double -Blind, Double -Dummy , Placebo -Controlled Study  To 
Evaluate The Safet y And Efficacy  Of 2 Regimens Of Orall y Administered 
PF-07321332/Ritonavir In Preventing S ymptomatic SARS -CoV -2 Infection I n Adult 
Household Contacts Of An Individual With Sy mptomatic COVID -19.
Brief Title: A Phase 2/3 Postexposure Prophy laxis Study  of PF -07321332/Ritonavir in Adult 
Household Contacts of an I ndividual with Sy mptomatic COVID -19
Rationale
The purpose of this stud y is to evaluate the efficacy and safet y of PF -07321332/ritonavir as 
postexposure prophy laxis for adult household contacts of an individual with sy mptomatic 
COVID -19.
Objectives, Endpoints, and Estimands
Objectives Endpoints Estimands
Primary: Primary: Primary: 
To compare the efficacy of 5 -day 
and 10 -day regimens of 
PF-07321332/ritonavir versus 
placebo in preventing 
symptomatic RT -PCR or rapid 
antigen test -confirmed 
SARS -CoV -[ADDRESS_1068979] a negative 
RT-PCR result at baseline:
Proportion of participants wh o 
develop a symptomatic, RT-PCR or 
rapid antigen test -confirmed 
SARS -CoV -2 infection through 
Day 14.The risk reduction between 5-day 
and 10 -day regimens of 
PF-07321332/ritonavir versus 
placebo in the proportion of 
individuals who develop 
symptomatic RT -PCR or rapid 
antigen test -confirmed 
SARS -CoV -[ADDRESS_1068980] 
to adherence to ran domized 
treatment.
Secondary: Secondary: Secondary: 
To describe the safety and 
tolerability of 5-day and 10 -day 
regimens of 
PF-07321332/ritonavir relative to 
placebo in adult participants who 
have a negative or positive 
RT-PCR result at baseline and 
who are household contacts of an 
individual with symptomatic 
COVID -19.Incidence of TEAEs
Incidence of SAEs and AEs leading 
to discontinuation.Not applicable.
To compare the efficacy of [ADDRESS_1068981] a negative 
RT-PCR result at baseline and who are The risk reduction between 5-day 
and 10 -day regimens of 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 15Objectives Endpoints Estimands
PF-07321332/ritonavir versus 
placebo in preventing 
symptomatic RT -PCR or rapid 
antigen test -confirmed 
SARS -CoV -[ADDRESS_1068982] a negative 
RT-PCR result at baseline, who 
are at increased risk of severe 
COVID -19 illness, and who are 
household contacts of an 
individual w ith symptomatic 
COVID -19.at increased risk of severe COVID-19 
illness:
Proportion of participants with 
symptomatic, RT-PCR or rapid 
antigen test -confirmed 
SARS -CoV -2 infection through 
Day 14.
Proportion of participants with 
COVID -19 related 
hospi[INVESTIGATOR_778360] 28.PF-07321332/ritonavir versus 
placebo in the proportion of 
individuals who develop 
symptomatic RT -PCR or rapid 
antigen test -confirmed 
SARS -CoV -[ADDRESS_1068983] 
to adherence to randomized 
treatment.
To compare the efficacy of 5 -day 
and 10 -day regimens of 
PF-07321332/ritonavir versus 
placebo in preventing 
SARS -CoV -[ADDRESS_1068984] a negative 
RT-PCR result at baseline:
Proportion of participants with 
asymptomatic RT -PCR or rapid 
antigen test-confirmed 
SARS -CoV -2 infection through 
Day 14.
Time to RT -PCR or rapid 
antigen test -confirmed 
SARS -CoV -[ADDRESS_1068985] a positive 
RT-PCR result at baseline:
Proportion of participants with 
symptomatic RT -PCR or rapid 
antigen test -confirmed 
SARS -CoV -[ADDRESS_1068986] a negative 
or positive RT -PCR result at baseline:
Proportion of participants with 
symptomatic RT -PCR or rapid 
antigen test -confirmed 
SARS -CoV -2 infection thro ugh 
Day 14.Not applicable.
To compare the efficacy of 5 -day 
and 10 -day regimens of 
PF-07321332/ritonavir versus 
placebo in the duration and 
severity of COVID -[ADDRESS_1068987] a negative 
RT-PCR result at baseline:
Proportion of participants with 
no, mild, moderate, or severe 
signs and symptoms attributed to 
COVID -19 through Day 28.
Number of days of symptomatic 
SARS -CoV -2 infection through 
Day 28.Not applicable.
To determine the PK of 
PF-[ADDRESS_1068988] a negative PF-07321332 PK in plasma and 
whole blood (if feasible).Not applicable.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 16Objectives Endpoints Estimands
or positive RT -PCR result at 
baseline and who are household 
contacts of an individual with 
symptomatic COVID -19.
To describe all -cause mortality in 
adult participants who have a 
negative RT -PCR result at 
baseline and who are household 
contacts of an individual with 
symptomatic COVID -19.Of the participants who have a negative 
RT-PCR result at baseline:
Proportion of participants with 
death (all -cause) through Day 38.Not applicable.
To describe the viral load in 
nasal samples over time in adult 
participants who have a negative 
or positive RT-PCR result at 
baseline and who are household 
contacts of an individual with 
symptomatic COVID -19.Of the participants who have a negative 
RT-PCR result at baseline:
Viral titers measured via RT-PCR 
in nasal swabs over time.
Of the participants who have a positive 
RT-PCR result at baseline:
Viral titers measured via RT-PCR 
in nasal swabs over time.Not applicable.
To describe hospi[INVESTIGATOR_778361] a 
negative RT -PCR result at 
baseline and who are household 
contacts of an individual with 
symptomatic COVID -19.Of the participants who have a negative 
RT-PCR result at baseline:
Number of days of hospi[INVESTIGATOR_778362] -19-related hospi[INVESTIGATOR_778363] 28.Not applicable.
To describe COVID -[ADDRESS_1068989] a negative 
RT-PCR result at baseline:
Number of COVID-19 related 
medical visits through Day 28.Not applicable.
Overall Design
Brief Summary
This Phase 2/3, randomized, double -blind, double -dummy , placebo- controlled study  in 
approximately  [ADDRESS_1068990] result and who are asymptomatic household contacts of individuals who are s ymptomatic 
and recently  tested positive for SARS -CoV -2 (index case: defined as patient with 
symptomatic COVID -19) will compare the efficacy
 of 2 regimens of PF -07321332/ritonavir 
versus placebo. Index cases may  be participants in Phase 2/3 safet y and efficacy s tudies of 
PF-07321332/ritonavir (C4671002 and C4671005), but this is not required. Eligible 
participants for this study will be randomly  assigned (1:1:1) within 96 hours after collection 
of the index case’s first positive SARS -CoV -[ADDRESS_1068991] to treatment in 1 of 3 intervention groups. 
Randomization will be stratified based on the presence of risk factors associated with severe 
COVID -19 illness and geographic region at screening.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 17Number of Participants
Assuming approximately 5% of participants will have a positive RT-PCR result at baseline, 
and assuming an approximately  10% dropout rate, the total sample size for this study  will be 
approximately  2880 participants . 
Note: "Enrolled" means a participant's, or his or her legally  authorized representative’s, 
agreement to participate in a clinical study following completion of the informed consent 
process and screening. A participant will be considered enrolled if the informed consent is 
not withdrawn prior to participating in an y study activity  after screening. Potential 
participants who are screened for the purpose of determining eligibility  for the study , but do 
not participate in the study, are not considered enrolled, unless otherwise specified b y the 
protocol. 
Intervention Grou ps and Duration
Eligible participants for this study  (C4671006) will be randomly  assigned (1:1:1) within 
96hours after collection of the index case’s first positive SARS -CoV -[ADDRESS_1068992] to receive: 
PF-07321332/ritonavir q12h for [ADDRESS_1068993] acebo q12h for 
5days; or
PF-07321332/ritonavir q12h for 10 day s; or 
Matching placebo for PF -07321332/ritonavir q12h for 10 day s.
Participants will be screened within 24 hours before randomization. The total duration of the 
study  is up to 42 day s and incl udes screening, study  intervention through Day 10, efficacy  
assessments through Day 14, and a safet y follow- up period through Day 38[±3days].
Data Monitoring Committee or Other Independent Oversight Committee: Yes
An independent E -DMC will review unblinded data to ensure the safet y of participants on an 
ongoing basis throughout the duration of the study. I n addition to up to weekly  reviews of 
safet y data, the E -DMC will review the following:
Sentinel cohort safet y review : The E -DMC will review unbl inded safet y data after 
approximately  the first [ADDRESS_1068994] completed Day 10 of the study , at which 
point enrollment will be paused pending E -DMC review of the safety data. After 
review of the sentinel cohort, the frequency  of safety  reviews may  be reduced 
subsequently  based on E -DMC recommendations.
Interim anal ysis: An interim analy sis will be conducted for efficacy , futility , and 
sample size re- estimation and reviewed b y the E -DMC after a prespecified accrual of 
participants (ie, before or at a pproximately  70% overall participants have completed 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 18the Day  14 assessments with a minimum number of 24 participants having 
symptomatic infection [mITT anal ysis set] ).
Statistical Methods
For the primary  efficacy  anal ysis, GEE will be used to anal yze the proportion of participants 
with a negative RT -PCR result at baseline who develop a s ymptomatic RT -PCR or rapid 
antigen test -confirmed SARS -CoV -2 infection through Day  14 for each treatment group. 
Comparisons between 5 -day regimen of PF -07321332/ritonavir ve rsus placebo group and 10-
day regimen of PF -07321332/ritonavir versus placebo group will be presented as risk 
reduction with 95% CIs based on GEE anal ysis.
Based on the results from Study  C4671005, which showed PF -07321332/ritonavir treatment 
significantl y reduced the risk of hospi[INVESTIGATOR_295340] y cause b y 89% compared 
with placebo in nonhospi[INVESTIGATOR_778364] -19 who were at 
increased risk of progression to severe disease when they  were treated within 3 day s of 
symptom onset, and the high relative risk reduction (approximately  80%) observed in 
Regeneron REGEN -COV post -exposure proph ylaxisstudy , the risk reduction between 
PF-07321332/ritonavir group versus placebo group is assumed to be 70%. The sy mptomatic 
infecti on rate assumption in the placebo group is adjusted to 4% based on the observed 
seropositivity  rate in this study  and the impact of seropositivity  on the incidence of primary  
endpoint events in the REGEN -COV post- exposure proph ylaxis study  where the incide nce of 
symptomatic infection was 2% in participants who were seropositive and 8% in those who 
were seronegative .2
Among baseline RT -PCR negative participants, assuming an 4% s ymptomatic infection rate 
in the placebo group, a 70% reduction in s ymptomatic infection ( 1.2% s ymptomatic infection 
rate) in the PF -07321332/ritonavir group (5
-day and 10 -day regimen), a sample size of 
821participants per group ( 2463 participants total) will provide approximately  90% power 
for each comparison between 5 -day and 10- day regimens of PF -07321332/ritonavir group 
versus placebo group under a 2 -sided t ype-1 error rate of 5%. Assuming ap proximately  5% 
of participants with negative rapid antigen test at screening will have a positive RT- PCR 
result at baseline, and assuming an approximately  10% dropout rate, the total sample size for 
this study  will be approximately  2880 participants.
An interim anal ysis will be conducted for efficacy, futility , and sample size re - estimation and 
reviewed b y an independent E- DMC after a prespecified accrual of participants (ie, before or 
at approximately  70% overall participants have completed the Day 14 asse ssments with a 
minimum number of 24 participants having s ymptomatic infection [mITT anal ysis set] ).

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 191.2.Schema

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 201.3.Schedule of Activities
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct eva luations or 
assessments required to protect the well -being of the participant. 
Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 14 .Screening Baseline
(Day 1)Day 3 Day 5 Day 10 Day 14 Day 28 Day 38 
EOSCOVID -19 
Signs/ 
Sym ptoms 
OnsetET NOTES
Visit Window Day -1 to 
Day 10 days ± 1 day ± 1 day ±1 day ±2 days ±2 days ±3 days +2 days 
ELIGIBILITY
Informed consent X See Section 10.1.3 .
Verify 
inclusion/exclusion 
criteriaX See Section 5.1and Section 5.2.
Demographics & medical 
historyX Will include assessment of prior 
documented infection and details of 
vaccination.
See Section 8.2.1 .
COVID -19 risk factor 
assessmentX See Appendix 11.
Index Case 
CharacteristicsX As permitted by [CONTACT_83344], index case 
characteristics will be collected 
through interview with the study 
participant to aid in characterization 
of the exposure period.
See Section 8.1.5

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 21Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 14 .Screening Baseline
(Day 1)Day 3 Day 5 Day 10 Day 14 Day 28 Day 38 
EOSCOVID -19 
Signs/ 
Sym ptoms 
OnsetET NOTES
Visit Window Day -1 to 
Day 10 days ± 1 day ± 1 day ±1 day ±2 days ±2 days ±3 days +2 days 
PHYSICAL EXAM AND VITAL SIGNS
Targeted physical 
examinationX X X X X X X [X] Will be completed at all in -person 
visits. In the event that an in -person 
visit is not feasible at the 
investigational site, targeted physical 
examinations and vital signs 
assessment may be performed by a 
licensed HCP at an alternate site 
approved by [CONTACT_093] (eg, the 
participant's home) when feasible.
AEs should be assessed by [CONTACT_3553] 
a telemedicine visit if not feasible 
during an in person visit.
Previously identified AEs (either by 
[CONTACT_30230], physical exam, or other 
assessment ) should be monitored to 
the extent possible if telemedicine is 
used.
Vital signs assessment at the 
COVID -19 Signs/Symptoms Onset 
visit will include oxygen saturation.
SeeSection 8.2.4 .Vital signs X X X X X X X [X]
Weight, height X See Section 8.2.2 .
CLINICAL LABORATORY TESTS
Hematology X X X X* X* [X] Screening visit: Laboratory 
assessments are not required at 
screening unless deemed necessary 
by [CONTACT_460266]. If deemed necessary, 
laboratory assessments at screening 
will be performed at the local 
laboratory. The medical labora tory 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 22Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 14 .Screening Baseline
(Day 1)Day 3 Day 5 Day 10 Day 14 Day 28 Day 38 
EOSCOVID -19 
Signs/ 
Sym ptoms 
OnsetET NOTES
Visit Window Day -1 to 
Day 10 days ± 1 day ± 1 day ±1 day ±2 days ±2 days ±3 days +2 days 
Blood chemistry X X X X* X* [X] test abnormalities within [ADDRESS_1068995] be closely 
assessed. If abnormalities cannot be 
verified, consider conducting local 
laboratory testing at screening to 
confirm eligibility for the study.
Baseline laboratory assessments 
should be collected prior to first dose 
of study intervention. If 
post-screening eGFR is 
<45mL/min/1.73m2, the participant 
will be instructed to discontinue any 
remaining study intervention doses 
as soon as study staff become aware 
of the eGFR results. If anoth er 
baseline laboratory result meets 
protocol Section 5.2exclusionary 
values and the participant is still 
receiving study treatment, contact 
[CONTACT_1689].
If a baseline laboratory result meets 
Section 5.2exclusionary laboratory 
values and the participant is still 
receiving study treatment, the 
investigator should contact [CONTACT_5134].
Abnormal laboratory values related 
to AEs should be followed until 
resolution. See Section 8.2.5 and
Appendix 2 .
*Safety laboratory tests at Days 14 
and 38 are required only if clinically 
significant abnormal laboratory 
values were present from a sample 
drawn at the previous study visit Other laboratory 
assessmentsX X X X X [X]

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 23Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 14 .Screening Baseline
(Day 1)Day 3 Day 5 Day 10 Day 14 Day 28 Day 38 
EOSCOVID -19 
Signs/ 
Sym ptoms 
OnsetET NOTES
Visit Window Day -1 to 
Day 10 days ± 1 day ± 1 day ±1 day ±2 days ±2 days ±3 days +2 days 
when laboratory assessments were 
performed.
At Day [ADDRESS_1068996] X X [X] A negative urine or serum (β-hCG) 
pregnancy test must be confirmed at 
Screening for WOCBP only.
Pregnancy tests will also be done 
whenever 1 menstrual cycle is 
missed during the active treatment 
period (or when potential pregnancy 
is otherwise suspected) and at Day 
38 or ET.
See Section 8.2.6 and Appendix 2 .
FSH X FSH is to be performed locally in 
female participants <60 years of age 
at Screening who are not using 
hormonal contraception or hormonal 
replacement therapy, to confirm 
postmenopausal status. Female 
participants aged 50 to 60 years with 
no menses for 12 months do not 
need FSH confirmation.
When FSH testing is required to 
confirm postmenopausal status, a 
participant may be enrolled in the 
study prior to the test result being 
available as long as the FSH test 
result confirms postmenopausal 
status prior to dosing.
See Section 10.4.3 and Appendix 2 .

PF-07321332
Protocol C4671006Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 24Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 14 .Screening Baseline
(Day 1)Day 3 Day 5 Day 10 Day 14 Day 28 Day 38 
EOSCOVID-19 
Signs/ 
Symptoms 
OnsetET NOTES
Visit Window Day -1 to 
Day 10 days ± 1 day ± 1 day ±1 day ±2 days ±2 days ±3 days +[ADDRESS_1068997] X X See Section [IP_ADDRESS] .
Collected as a separate swab from nasal 
swab, specifically for local testing.
Nasal swab Daily from Day 1 through Day 14 X X •At baseline, a nasal swab will be self 
collected by [CONTACT_778404]-PCR status (+ or -); this test will not be used to 
determine study eligibility. The 
baseline sample will be collected under observation by [CONTACT_778405]. 
Thereafter, nasal swabs will be self 
collected by [CONTACT_778406], preferably in the morning, except on Day 5, Day 10, Day 14, or during any 
COVID-19 Signs and Symptoms 
Onset visit or unplanned visit, in which case, the nasal swab should be collected by [CONTACT_82275].
•On the days where there is an 
in-person visit, the nasal swab 
should be collected by [CONTACT_778407]
•See Section [IP_ADDRESS] . and
Section 8.6.5 .
Specified protein research 
(plasma biomarkers)X X X See Section 8.6.2 .
CCI
PF-07321332
Protocol C4671006Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 25Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 14 .Screening Baseline
(Day 1)Day 3 Day 5 Day 10 Day 14 Day 28 Day 38 
EOSCOVID-19 
Signs/ 
Symptoms 
OnsetET NOTES
Visit Window Day -1 to 
Day 10 days ± 1 day ± 1 day ±1 day ±2 days ±2 days ±3 days +2 days 
Retained research 
samples for biomarkers (Prep B2)XX X X •See Section 8.6.5 .
PHARMACOKINETIC
S
PK Sample 
(PF-07321332)XX •On Day 1, one blood sample for PK 
will be collected [ADDRESS_1068998] dose onsite and are 
able to remain onsite following dose 
administration. 
•On Day 5, one blood sample for PK 
will be collected predose (up to 2 hours before study intervention administration) if feasible; otherwise, collect anytime during the 
visit.
•SeeSection 8.4 .
Optional PK samples 
(self collected by [CONTACT_3445])X •Whole blood self-collected PK 
samples using the Tasso 
microsampling device (selected sites, 
if feasible) at the following times:
• Day 3: after the morning dose 
at the following times: o1 sample between 30 to 
90 minutes, 
o1 sample between 2 to 6 
hours, and 
o1 sample 8 to 12 hours 
after the dose (the last 
sample should be collected 
before the evening dose).CCI
PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 26Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 14 .Screening Baseline
(Day 1)Day 3 Day 5 Day 10 Day 14 Day 28 Day 38 
EOSCOVID -19 
Signs/ 
Sym ptoms 
OnsetET NOTES
Visit Window Day -1 to 
Day 10 days ± 1 day ± 1 day ±1 day ±2 days ±2 days ±3 days +2 days 
SeeSection 8.4.
RANDOMIZATION X
STUDY INTERVENTION
Study intervention 
dispensationX X Study intervention will be dispensed 
on Day 1 and Day 5 (see
Section 6.1.1 ).
Day 5 visit has to be scheduled on 
time to dispense study intervention 
prior to the 11th dose which should 
be on the morning of study Day 6 if 
2 doses were taken on Day 1 or on 
the evening of study Day 6, if a 
single dose was taken on Day 1.  
Study intervention 
administrationDaily from Day 1 through Day 10 For Treat ment Days : Participants 
will receive [ADDRESS_1068999] 4 hours later so 
that the dosing schedule is 
convenient for the participant. All 
subsequent doses will be q12h [±30 
minutes]. 
The last day of treatment will be Day 
[ADDRESS_1069000]/update secondary 
contact[CONTACT_295408] X X X X X On Day 1, the investigator will collect 
contact [CONTACT_514077] 
2 individuals who can be contact[CONTACT_778408] (repeat/update as 
needed). 
Record/update household 
characteristicsX X X X X X X X See Section 8.1.6 .

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 27Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 14 .Screening Baseline
(Day 1)Day 3 Day 5 Day 10 Day 14 Day 28 Day 38 
EOSCOVID -19 
Signs/ 
Sym ptoms 
OnsetET NOTES
Visit Window Day -1 to 
Day 10 days ± 1 day ± 1 day ±1 day ±2 days ±2 days ±3 days +[ADDRESS_1069001] supplemental 
oxygen requirementsX X X X X X X X See Section 8.1.4 .
Study kit dispensed and 
participant instructed on 
its useX The study kit includes documents and 
materials that will facilitate participant 
completion of at -home study 
procedures.
Participant-completed 
study diary (COVID -19 
signs and symptoms and 
global impression 
questions)Daily from Day 1 through Day 28 Global impression questions will be 
answered every day from the first 
day a symptom is reported in the 
diary through Day 28.
These assessments will be answered 
on the day of the COVID -19 Signs/ 
Symptoms Onset visit or the ET visit 
if the visit occurs from Day 1 
through Day 28. 
For participants who are using an 
eDiary provid ed through the study, 
the eDiary will be collected on Day 
38 or ET visit, after completion of 
all logs and questionnaires executed 
on the device.
See Section 8.1.1 and Section [IP_ADDRESS] .
EQ-5D-5L X X X X X If supported by [CONTACT_79152], PRO 
assessments will be reported by 
[CONTACT_778409] 
(Section 8.1.1 ). 
See Section 8.1.7 .WPAI X X X
Staff review of study 
diaryX X X X X X X X
Participant completes 
study intervention logDaily from Day 1 through Day 10 The last day of treatment will be 
Day 10 or Day 11, depending on 
how many doses were administered 
on Day 1.
Study intervention log will be 
completed on the day of the 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 28Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 14 .Screening Baseline
(Day 1)Day 3 Day 5 Day 10 Day 14 Day 28 Day 38 
EOSCOVID -19 
Signs/ 
Sym ptoms 
OnsetET NOTES
Visit Window Day -1 to 
Day 10 days ± 1 day ± 1 day ±1 day ±2 days ±2 days ±3 days +2 days 
COVID -19 Signs/ Symptoms Onset 
or ET visits if the visit occurs from 
Day [ADDRESS_1069002] visitX X X X X X Day 10 : Record visits since 
randomization.
All subsequent visits : Record 
COVID -19 related medical visits 
since the prior assessment/visit.
See Section 8.1.3
Retrieval of unused 
study intervention and 
empty study intervention 
containersX X X X [X] Empty study intervention containers 
and unused study intervention 
should be returned at the next in -
person visit.
SeeSection 6.4. Study intervention 
accountabilityX X [X] if 
needed
Contraception check X X X X X X X X X See Appendix [ADDRESS_1069003] 
prior/concomitant 
medication(s)X X X X X X X X X All prescription and over-the -counter 
medications being taken by [CONTACT_778410] 
14days before study entry 
(considered prior treatment) will be 
recorded. 
Refer to Section 6.8.
Record adjunctive 
therapeutic proceduresX X X X X X X X X Nondrug treatments.
Collected only if the participant 
becomes symptomatic.
SERIOUS AND 
NONSERIOUS AE 
MONITORINGX X X X X X X X X AEs should be assessed by [CONTACT_3553] 
a telemedicine visit if not feasible 
via an in -person visit. 
Refer to Section 8.3.
Site staff should, in discussion with participants, determine the most appropriate location to conduct study visits, whether in-person or remotely by [CONTACT_144891]. In person 
visits should take place at the investigational site. If investigational site in -person visit is not feasible, then alternate venues may include the participant's home or an alternate, 
noninvestigational site location approved by [CONTACT_093]. If an in -person visit is held at a location other than the investigational site, in certai n situations the assigned HCP 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 29Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 14 .Screening Baseline
(Day 1)Day 3 Day 5 Day 10 Day 14 Day 28 Day 38 
EOSCOVID -19 
Signs/ 
Sym ptoms 
OnsetET NOTES
Visit Window Day -1 to 
Day 10 days ± 1 day ± 1 day ±1 day ±2 days ±2 days ±3 days +2 days 
performing the visit may be unable to complete all assessments. In these cases, a telemedicine visit should also occur to per form the remaining assessments. Remote visits can 
be conducted using a telemedicine system approved f or use at the site. 
Assessments indicated in brackets [X] will be performed only for in -person visits.
Screening procedures may be done from Day -1 to Day 1. In many cases, all screening procedures can be completed in <24 hours. For these participants, sc reening procedures 
may be completed on the same calendar day as randomization and Baseline/Day [ADDRESS_1069004] dose of study inter vention.
Baseline assessments should be performed before the administration of the first dose of study intervent ion.
Day 1 is the start of dosing.
Study Intervention Dispensation: Participants will receive their first set of study intervention containers at the Day 1 visit and the second set of study intervention containers 
at the Day 5 visit. Each set contains 10 d oses of study intervention. Day 5 visit should be scheduled so that there is no interruption in dosing and so the participant does not use 
any overage from the set dispensed at the Day 1 visit (see Section 6.2.1 ). 
For Study Intervention Administration : Participants will receive study intervention for 10 days (20 doses total). The first dose will be administered at the Basel ine/Day 1 
visit during the in -person visit, if possible. All subsequent doses (ie, 19) will be self administered outside the study clinic (eg, at home).
Screening , Baseline , Day 5, Day 10, Day 14 and Day 38 visits will be conducted in person (at the investigational site or another location, including a participant’s home) 
provided the planned assessments can be performed at the location selected.
Day 3 visit involves self -collected PK samples (using Tasso) o nly for participants who consent to the optional PK sampling. There is no planned in -person or telemedicine visit 
on this study day.
Day 3 and Day 5 visits should be conducted on separate calendar days.
Day 28 visit will be conducted by [CONTACT_295412] .
COVID -19 Signs/Symptoms Onset visit will occur as soon as possible after the participant experiences signs or symptoms of COVID -19 and will be conducted in -person any 
time up to Day 38. When the COVID -19 Signs/Symptoms Onset visit occurs within the visit window prior to a scheduled visit, the 2 visits can be combined.
Early Termination visit will be conducted in person or by [CONTACT_295412].
Telemedicine Visits , while planned to be virtual (ie, over the phone or other approved system), they may also be conducted in -person at the investigator’s discretion.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 302.INTRODUCTION
PF-07321332, a potent and selective SARS- CoV -2 3CL  protease inhibitor, is being 
investigated as oral antiviral postexposure prophy laxis for adult household contacts of an 
individual with sy mptomatic COVID -19.
2.1.Study Rationale 
The purpose of this stud y is to evaluate the efficacy and safet y of PF -07321332/ritonavir as 
postexposure prophy laxis for adult household contacts of an individual with sy mptomatic 
COVID -19.
2.2.Back ground 
In December 2019, COVID -[ADDRESS_1069005] (approximately  80%) cases are as ymptomatic 
or mild,6patients who are hospi[INVESTIGATOR_21391] -[ADDRESS_1069006] (approximately  80%) cases are 
asymptomatic or mild,6patients who are hospi[INVESTIGATOR_21391] -[ADDRESS_1069007] significant 
morbidity  and mortality ,7,8and are at increased risk of developi[INVESTIGATOR_778365], ARDS, acute 
cardiac injury , thromboembolic events, hy percoagulability , and/or kidney  injury .9-12
Moreover, other comorbidities, such as hy pertension, obesity , and diabetes, as well as older 
age and male sex increase the risk for worse outcomes.7
Although there are s ymptomatic and/or supportive treatments for COVID -19, few antiviral 
drugs are available or in late-stage development to help treat COVID- 19 in patients with mild 
to moderate COVID -19. Existing compounds, such as hy droxy chloroquine and 
lopi[INVESTIGATOR_054]/ritonavir, have been evaluated as potential treatment options for COVID -19, but
have not demonstrated benefit or efficacy  beyond the SoC.13-15The FDA has approved IV 
remdesivir,16an antiviral drug with activity  against SARS -CoV -2, for hospi[INVESTIGATOR_295344] D-19. However, remdesivir monotherapy  may  not be sufficient in all subsets of 
patients17across the COVID -[ADDRESS_1069008] li mited its clinical use.20

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 31Among contacts of persons with COVI D-19, the percentage in whom new cases develop 
(secondary  attack rate) has been estimated at 10 to 15%.23-26The primary infection -control 
strategy  currentl y employed relies on basic h ygiene measures such as hand washing, use of 
personal protective equipment such face masks, social distancing, and isolation of case 
patients and their contacts.27The effectiveness of isolation depends on the promptness of the 
intervention, the level of contact [CONTACT_144842], and the level of isolation adherence28. 
Implement ation of these measures however, has not been fully  effective and spread of 
SARS -CoV -2 in many  countries continues to occur. Furthermore, modeling of SARS- CoV -2 
viral shedding d ynamics suggests that up to 44% of transmission occurs prior to sy mptom 
onset of the index case (pres ymptomatic transmission) and that start and peak infectiousness 
can be up to 2 day s before sy mptom onset.29
There are large efforts in progress to develop vaccines30with several now authorized for 
emergency  use or conditionally  approved b y Health Authorities for those aged 12 years and 
older.31These vaccines will take time to deploy and may not be taken b y everyone. Also, the 
duration of potential protection is not known leading to continued efforts to identify  effective 
antiviral treatments. Moreover, currentl y authorized/approved vaccines may not be as 
effective against potential outbreaks from new coronavi rus variants.32,33Emergence of the 
Omicron variant in late [ADDRESS_1069009] been observed.35
Postexposure prophy laxis for healthy  contacts is among the measures used for outbreak 
control of several infectious diseases (eg, pandemic influenza).36No oral agents are known to 
be effective in preventing SARS- CoV -2 infection or COVID -19, but aminoquinolines 
(hydroxy chloroquine and chloroquine) and antiretrovirals (eg, lopi[INVESTIGATOR_054]/ritonavir) have been 
or are in the process of being assessed for potential utility  in the postexposure, preemptive 
treatment/proph ylaxis outpatient settings.37The direct reduction of viral replication, through 
inhibition of other critical viral enzy mes, offers an important mechanism to achieve greater 
patient benefit and perhaps aid in control of the COVID -19 pandemic. The US FDA has 
granted EUA for an IV-or SC -administered mAb regimen as postexposure prophy laxis for 
COVID -19 in adults and adolescents who are at high risk for progressing to se vere COVID -
19.38As of January  2022, no orally  administered therapeutic intervention has been approved 
or authorized for use in postexposure/preemptive treatment/proph ylaxis.
The cor onavirus 3CL  protease is a virall y encoded enzy me that is critical to the 
SARS -CoV -2 replication cycle, analogous to other obligatory virally encoded proteases 
(eg,HIV Protease, HCV Protease).39Mutagenesis experiments with other coronaviruses and 
pi[INVESTIGATOR_295346] -CoV -2 (pi[INVESTIGATOR_295347]- like supercluster) have 
demonstrated that the activity  of the 3CL protease (or the corresponding pi[INVESTIGATOR_295348] 
3Cenzyme) is essential for viral replication. No close human analogs of coronavirus 3CL  

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 32enzy mes are known, suggesting that appropriate 3CL  inhibitors may  function as selective 
inhibitors of SARS -CoV -2 and other coronaviruses as therapeutic agents.
PF-07321332, a potent and selective inhibitor of the SARS- CoV -2 3CL  protease, is being 
developed as an oral treatment and/or postexposure prophy laxis in patients with COVI D-19.
In this stud y, PF -[ADDRESS_1069010] an y antiviral activity  on the SARS -CoV -2 virus and is being used only  as a PK 
enhancing agent .
2.2.1. Nonclinical Studies of PF-07321332
Data from nonclinical studies support the planned clinical trials with PF -07321332; these 
studies are described in the IB.[ADDRESS_1069011] article -related findings identified in the safety pharmacology studies included changes in 
locomotor activity  and transient higher respi[INVESTIGATOR_778366], as well as minor and transient hemod ynamic changes (increased blood pressure and 
decreased heart rate) at the high dose in cy nomolgus monkey s. The potential effects on safet y 
pharmacology  parameters are monitorable in the clinic, and no correlated clinical signs or 
histopathological findings in the relevant organs were observed in the [ADDRESS_1069012] article -related changes in ECG parameters 
(HR, RR -, PR-, QRS -, QT- , QTc -intervals) or ECG morphology  in that study .
2.2.2. Clinical Overview
C4671001 ([STUDY_ID_REMOVED]) is an ongoing FIH single and multiple dose escalation study  to 
evaluate the safet y, tolerability , and PK of PF -07321332 in healthy  adult participants. 
Preliminary  data from this study  collected as of 07 April 2021 (SAD) and 14 April 2021 
(MAD) in a total of 31 participants who were randomized and treated with PF -07321332 or 
placebo, the clinical safety profile of PF 07321332 appears to be acceptable at single doses 
up to 1500 mg alone and up to 750 mg administered with ritonavir (100 mg at -12h, 0h, 12h), 
and at repeated da ily doses administered orally  for 10 day s of up to 500 mgPF-07321332 
BID with 100 mg ritonavir BID.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 33Preliminary  PK data on Day  1, Day  5 and Day  10 following multiple oral administration of 
PF-07321332/ritonavir 75/100 mg, 250/100 mg, and 500/[ADDRESS_1069013] common reported AE, occurring in 4 participants across treatment 
groups. A total of 5 treatment related TEAEs were observed in Part -2:MAD.
Across treatment groups, blood TSH increase d in 3 participants, and 2 participants reported 
dysgeusia. The 3 participants with elevated TSH results did not experience related clinical 
symptoms and the free T4 results remained within reference range. No SAEs or deaths were 
reported based on these pr eliminary  safety  data as of 07 April 2021 and 14 April 2021.
Current evidence indicates the clinical safet y profile of PF 07321332 is acceptable at single 
doses up to 1500 mg alone and up to 750 mg administered with ritonavir (100 mg at -
12h, 0h, 
12h), and at repeated daily  doses administered orally  for 10 day s of up to 500 mg 
PF-07321332 BID with 100 mg ritonavir BID.
C4671005 ( [STUDY_ID_REMOVED]), a Phase 2/3, randomized, double -blind, placebo -controlled study  
in nonhospi[INVESTIGATOR_778367] a laboratory -confirmed diagnosis of 
SARS -CoV -[ADDRESS_1069014] 1 risk 
factor for progression to severe disease and with a COVID
-19 s ymptom onset of 
≤5days.The study  excluded individuals with a history  of prior COVID -19 infection or 
SARS -CoV -2 vaccination before the Day  34 visit. The primary  efficacy  endpoint was the 
proportion of participants with COVI D-19 related hospi[INVESTIGATOR_778368] 28. 
In the anal ysis of the pr imary  endpoint from all participants enrolled in Study  C4671005, an 
89% reduction in COVID-19- related hospi[INVESTIGATOR_295340] y cause compared with 
placebo in participants treated within 3 day s of s
ymptom onset was observed. 0.7% of 
participants wh o received PF -07321332/ritonavir were hospi[INVESTIGATOR_119839]  28 
following randomization (5 of 697 hospi[INVESTIGATOR_493707]), compared to 6.5% of 
participants who received placebo and were hospi[INVESTIGATOR_47163] (44 of 682 hospi[INVESTIGATOR_191546] 
9 subsequent deaths) (p<0.0001). In a secondary  endpoint, PF -07321332/ritonavir reduced 
the risk of hospi[INVESTIGATOR_778369] y cause by 88% compared with placebo in 
participants treated within 5 day s of sy mptom onset; 0.8% of patients who received 
PF-07321332/rit onavir were hospi[INVESTIGATOR_382181]  28 following randomization 
(8of 1039 hospi[INVESTIGATOR_493707]) compared with 6.3% of patients who received 
placebo (66 of 1046 hospi[INVESTIGATOR_191546] 12 subsequent deaths) (p<0.0001). Treatment with 
PF-07321332/r itonavir was safe and well tolerated.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 34Results from a protocol -specified interim analy sis of Study  C4671002 ([STUDY_ID_REMOVED]), 
which included 45% of the study ’s planned enrollment, showed that the novel primary  
endpoint of self -reported, sustained alleviation of all sy mptoms for 4 consecutive day s, as 
compared with placebo, was not met. However, the key  secondary  endpoint of 
COVID -19-related hospi[INVESTIGATOR_493701]  28 was also 
examined at the interim analy sis, showing 0.6% of those w ho received 
PF-07321332/ritonavir were hospi[INVESTIGATOR_778370] (2 of 333 hospi[INVESTIGATOR_778371]), compared to 2.4% of participants who received placebo and were 
hospi[INVESTIGATOR_057] (8 of 329 hospi[INVESTIGATOR_493707]). 
2.3.Benefit/Risk Assessment
More detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs of PF -07321332 may  be found in the investigator’s brochure, which is the 
SRSD for this study . The SRSD for the ritonavir is the 
USPI41for NORVIR.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 352.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s) PF-07321332
Emesis Sporadic emesis was observed at ≥100 mg/kg/day of 
PF-07321332 in the 15 -day NHP toxicology study.AEs will be monitored and participants may 
receive antiemetics.
Hem odynamic and inflammatory effects Low level inflammation (increase in fibrinogen) in 
15-day NHP toxicology study and changes in 
platelets, globulin and albumin/globulin ratio and 
coagulation system (increase in PT and aPTT) in 
14-day rat toxicology study.In addition to vital signs and close observation for 
AEs, fibrinogen, platelets, D -dimer, PT and aPTT, 
albumin, and total protein will also be monitored.
Refer to Section 8.3.8 .
TSH elevationsTSH changes observed with the administration of 
PF-07321332 during study C4671001TSH and T4 (free) w ill be monitored.
Refer to Section 8.3.8 .
Study Intervention(s): Ritonavir
Gastrointestinal disturbances (including 
diarrhea, nausea, vomiting and abdominal pain)Frequently reported adverse reaction in patients who 
are HIV -positive at 600 mg BID.Lower dose of 100 mg twice daily is used in this 
study. There will be close observation of AEs. 
In addition to ongoing revie w of AEs by [CONTACT_103], an E -DMC will review safety data as 
described in Section [IP_ADDRESS] .
Taking study i ntervention with food may improve 
tolerability.
Neurological disturbances (eg, paresthesia, 
including oral paresthesia, dysgeusia and 
dizziness)Frequently reported adverse reaction in patients who 
are HIV -positive at 600 mg BID.Lower dose used in this study. There w ill be close 
observation of AEs.  
In addition to ongoing revie w of AEs by [CONTACT_103], an E -DMC will review safety data as 
described in Section [IP_ADDRESS] .
Rash (most commonly reported as erythematous 
and maculopapular, followed by [CONTACT_108135])Frequently reported adverse reaction in patients who 
are HIV -positive at 600 mg BID.Lower dose used in this study. There w ill be close 
observation of AEs and monitoring through 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 36Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
targeted physical exams. If needed therapeutic 
interventions per SoC may be provided.
Fatigue/Asthenia Frequently reported adverse reaction in patients who 
are HIV -positive at 600 mg BID .Lower dose used in this study. There w ill be close 
observation of AEs. Fatigue (low  energy or 
tiredness) will be assessed through collection of 
daily signs and symptoms and w ill also be 
assessed through targeted physical examinations 
when performed durin g the study visits.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 372.3.2. Benefit Assessment
As of January  2022, no orally  administered therapeutic intervention has been approved or 
received an EUA in the US for use in postexposure/preemptive treatment/prophy laxis , but 2 
orally  
administered antivirals for the treatment of COVID-19 in patients at high risk of 
progression to severe COVID- 19 (eg, Paxlovid42and molnupi[INVESTIGATOR_42654]43) have begun receiving 
EUAs (or equivalent) in various regions. Additionally , the emergence of variants such as the 
omicron variant that may be associated with reduced protection afforded b y vaccine and 
monoclonal antibodies further emphasizes the need for additional treatment and postexposure 
prophy laxis options.34,35On this basis, the potential benefit to individual study  participants 
who receive the study  intervention may include preventing development of sy mptomatic 
SARS -CoV -[ADDRESS_1069015] (an index patient) with 
symptomatic COVID -19. By  [CONTACT_778411] -CoV -2 infection, there is the potential benefit of early detection and 
subsequent medical management should infection with SARS -CoV -2 be detected.
2.3.3. Overall Benefit/Risk Conclusion
Taking into account the seriousness of COVID -19, the lack of rea dily available postexposure 
prophy lactic treatment options and the measures taken to minimize risk to participants in this 
study , the potential risks identified in association with PF -07321332 are justified by  [CONTACT_778412] -CoV -2 infection. An independent E -DMC will be responsible for 
monitoring the safety of participants at regularl y scheduled intervals throughout the duration 
of the study  and for assessing efficacy , futility , and sample size re -estimation at the time of 
the interim anal ysis according to the E -DMC charter.
3.OBJECTIVES, ENDPOINT S, AND ESTIMANDS
Objectives Endpoints Estimands
Primary: Primary: Primary: 
To compare the efficacy of 5 -day 
and 10 -day regimens of 
PF-07321332/ritonavir versus 
placebo in preventing 
symptomatic RT -PCR or rapid 
antigen test -confirmed 
SARS -CoV -[ADDRESS_1069016] a negative 
RT-PCR result at baseline:
Proportion of participants who 
develop a symptomatic, RT- PCR 
or rapid antigen test--confirmed 
SARS -CoV -2 infection through 
Day 14.The risk reduction between 5-day 
and 10 -day regimens of 
PF-07321332/ritonavir versus 
placebo in the proportion of 
individuals who develop 
symptomatic RT -PCR or rapid 
antigen test --confirmed 
SARS -CoV -[ADDRESS_1069017] 
to adherence to randomized 
treatment. 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 38Objectives Endpoints Estimands
Secondary: Secondary: Secondary: 
To describe the safety and 
tolerability of 5-day and 10 -day 
regimens of 
PF-07321332/ritonavir relative to 
placebo in adult participants who 
have a negative or positive 
RT-PCR result at baseline and 
who are household contacts of an 
individual with symptomatic 
COVID -19.Incidence of TEAEs
Incidence of SAEs and AEs leading 
to dis continuation.Not applicable.
To compare the efficacy of 5 -day 
and 10 -day regimens of 
PF-07321332/ritonavir versus 
placebo in preventing 
symptomatic RT -PCR or rapid 
antigen test -confirmed 
SARS -CoV -[ADDRESS_1069018] a 
negative RT -PCR result at baseline 
and who are at increased risk of 
severe COVID -19 illness:
Proportion of participants with 
symptomatic, RT-PCR or rapid 
antigen test -confirmed 
SARS -CoV -2 infection through 
Day 14.
Proportion of participants with 
COVID -19 related 
hospi[INVESTIGATOR_778360] 28.The risk reduction between 5 -day 
and 10 -day regimens of 
PF-07321332/ritonavir versus 
placebo in the proportion of 
individuals who develop 
symptomatic RT -PCR or rapid 
antigen test --confirmed 
SARS -CoV -[ADDRESS_1069019] 
to adherence to randomized 
treatment.
To compare the efficacy of 5 -day
and 10 -day regimens of 
PF-07321332/ritonavir versus 
placebo in preventing 
SARS -CoV -[ADDRESS_1069020] a negative 
RT-PCR result at baseline:
Proportion of participants with 
asymptomatic RT -PCR or rapid 
antigen test --confirmed SARS -
CoV -2 infection through Day 14.
Time to RT -PCR or rapid 
antigen test --confirmed SARS -
CoV -[ADDRESS_1069021] a positive 
RT-PCR result at baseline:
Proportion of participants with 
symptomatic RT -PCR or rapid 
antigen test --confirmed SARS -
CoV -[ADDRESS_1069022] a negative 
or positive RT -PCR result at baseline:
Proportion of participants with 
symptomatic RT -PCR or rapid 
antigen test --confirmed SARS -
CoV -2 infection through Day 14.Not applicable.
To compare the efficacy of 5 -day 
and 10 -day regimens of 
PF-07321332/ritonavir versus 
placebo in the duration and Of the part icipants who have a negative 
RT-PCR result at baseline:
Proportion of participants with 
no, mild, moderate, or severe Not applicable.

PF-[ADDRESS_1069023] a negative 
RT-PCR result at baseline and 
who are household contacts of an 
individual with symptomatic 
COVID -19.signs and symptoms attributed to 
COVID -19 through Day 28.
Number of days of symptomatic 
SARS -CoV -2 infection through 
Day 28.
To determine the PK of 
PF-[ADDRESS_1069024] a negative 
or positive RT -PCR result at 
baseline and who are household 
contacts of an individual with 
symptomatic COVID -19.PF-07321332 PK in plasma and 
whole blood (if feasible).Not applicable.
To describe all -cause mortality in 
adult participants who have a 
negative RT -PCR result at 
baseline and who are household 
contacts of an individual with 
symptomatic COVID -19.Of the participants who have a negative 
RT-PCR result at baseline:
Proportion of participants with 
death (all -cause) through Day 38.Not applicable.
To describe the viral load in 
nasal samples over time in adult 
participants who have a negative 
or positive RT-PCR result at 
baseline and who are household 
contacts of an individual with 
symptomatic COVID -19.Of the participants who have a negative 
RT-PCR result at baseline:
Viral titers measured via RT-PCR 
in nasal swabs over time.
Of the participants who have a positive 
RT-PCR result at baseline:
Viral titers measured via RT -PCR 
in nasal swabs over time.Not applicable.
To describe hospi[INVESTIGATOR_778361] a 
negative RT -PCR result at 
baseline and who are household 
contacts of an individual with 
symptomatic COVID -19.Of the participants who have a negative 
RT-PCR result at baseline:
Number of days of hospi[INVESTIGATOR_778362] -19-related hospi[INVESTIGATOR_778363] 28.Not applicable.
To describe COVID -[ADDRESS_1069025] a negative 
RT-PCR result at baseline:
Number of COVID-19 related 
medical visits through Day 28.Not applicable.
4.STUDY DESIGN
4.1.Overall Design
This Phase 2/3, randomized, double -blind, double -dummy , placebo- controlled study  will 
compare the efficacy  of 2 regimens of PF -07321332/ritonavir versus placebo in 
approximately  [ADDRESS_1069026] result and are as ymptomatic household contacts of individuals who are sy mptomatic and 
recentl y tested positive for SARS -CoV -2 (index case: defined as patient with symptomatic 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 40COVID -19). Index cases may  be participants in Phase 2/3 safet y and efficacy  studies of 
PF-07321332/ritonavir (C4671002 and C4671005), but this is not required. Eligible 
participants for this study will be randomly  assigned (1:1:1) within 96 hours after collection 
of the index case’s first positive SARS -CoV -[ADDRESS_1069027] to receive: 
PF-07321332/ritonavir q12h for 5 day s followed by  [CONTACT_51093] q12h for 
5days; or
PF-07321332/ritonavir q12h for 10 day s; or 
Matching placebo for PF -07321332/ritonavir q12h for 10 day s.
Randomization will be stratified based on the presence of risk factors associated with severe 
COVID -19 illness (see Appendix 11 ) and geographic region at screening. Throughout the 
study  period, provision will be made to allow study visits to be conducted at a participant’s 
home or at another nonclinic location approved b y the investigator where possible when 
participants are unwilling or unable to attend a clinic visit at the investigational site. 
Participants will be screened within 24h before randomization. The total duration of the study  
is up to 42 day s and includes screening, study  intervention through Day  10, efficacy  
assessments through Day 14, and a safet y follow- up period through Day 38[±3 day s]. 
An independent E -DMC will review unblinded data to ensure the safet y of participants on an 
ongoing basis throughout the duration of the study. I n addition to up to weekly  reviews of 
safet y data, the E -DMC will review the following:
Sentinel cohort safet y review : The E- DMC will review unblinded safet y data after 
approximately  the first [ADDRESS_1069028] completed Day 10 of the study , at which 
point enrollment will be paused pending E -DMC review of the safety data. After 
review of the sentinel cohort, the frequency  of safety  reviews may  be reduced 
subsequently  based on E -DMC recommendations.
Interim anal ysis: An interim analy sis will be conducted for efficacy , futility , and 
sample size re- estimation and reviewed by [CONTACT_1629] E -DMC after a prespecified accrual of 
participant s (ie, before or at approximately  70% participants have complete dthe 
Day 14 assessments with a minimum number of 24 participants having s ymptomatic 
infection [mITT anal ysis set] ).
Subsequent to the planned interim analy sis, there will be a single anal ysis for reporting the 
results of this study  after all participants have had their last study  visit. 
4.2.Scientific Rationale for Study Design
This study  evaluates safety  and the potential efficacy  of an investigational agent on 
preventing s ymptomatic SARS -CoV -
2infection (postexposure prophy laxis) in household 
contacts of individuals who recentl y tested positive for SARS -CoV -2 and are s ymptomatic 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 41(ie, index case: patient with sy mptomatic COVID -19). Prior studies of antiviral, mAb, and 
antimalarial agents have ev aluated the efficacy of these agents as postexposure prophy laxis 
and/or preemptive treatment for s ymptomatic SARS -CoV -[ADDRESS_1069029] -exposure treatment of as ymptomatic patients may  reduce sy mptomatic 
SARS -CoV -2 infection.37,44-49
Efficacy  assessments (including coll ection of nasal swabs and participant- reported 
COVID -19 s ymptoms) will be collected through Day  [ADDRESS_1069030] to confirm SARS -CoV -2 infection so that the 
participants may  receive SoC therapy  as described in Section 6.8. Additional testing may  be 
performed in accordance with local medical practice. 
This study  uses a randomized, double -blind, double -dummy , placebo
-controlled design, 
which is a well -accepte d approach for evaluating efficacy  in a clinical research setting.
4.2.1. Diversity of Study Population
Reasonable attempts will be made to enroll participants to ensure the stud y population is 
representative of the patient population that will be treated with PF -07321332/ritonavir in 
clinical practice.
4.2.2. Choice of Contraception/Barrier Requirements
Studies to evaluate the developmental toxicity  of PF -[ADDRESS_1069031] not been conducted. 
Therefore, the use of a highly effective method of contraception is required (see Appendix 4 ).
4.2.3. Collection of Retained Research Samples
Retained Research Samples will be collected and stored for further anal yses which may , for 
example, provide greater understanding of the study  intervention.
4.3.Justification for Dose
Dosing regimens of 300 mg PF- 07321332 coadministered with 100 mg ritonavir q12h 
administered orall y for 5 days or 10 days will be evaluated in this study. Dose selection for 
this study  included consideration of all relevant available preclinical and clinical data, 
including repeat -dose toxicology  studies, clinical safet y, and PK data from the Phase 1 study 
(C4671001), and in vitro pharmacology  studies with PF -07321332.
A preliminary  population PK model was developed from the Phase 1 (C4671001) PK data. 
Following a first dose of 300 mg PF -
07321332 coadministered with 100 mg ritonavir q12h, 
median C trough of unbound (free) PF -07321332 is predicted to be approximately 289 ng/mL 
(equivalent to 933 ng/mL total), ie, approximately  3-fold hi gher than the in vitro EC 90of 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 4290.4 ng/mL determined in dNHBE cells (equivalent to 181 nM, f u, human=0.310). At this 
dose, for a h ypothetical intersubject variability  of 60%, more than 95% of the participants are 
predicted to maintain free PF -[ADDRESS_1069032] -exposure prophy laxis in household contacts exposed to persons with 
COVID -19, the efficacy  and safet y of 5-and 10 -day treatment durations will be assessed in 
this study .
Preliminary  safet y data from study  C4671001, collected up to 07 April 2021 for PART- 1 and 
14 April 2021 for PART -2, showed an acceptable safet y profile for single doses of 
PF-07321332 ran ging from 150 mg to 1500 mg dosed alone and of 250 mg and 750 mg 
dosed with ritonavir (100 mg administered at - 12h, 0h, 12h) and for [ADDRESS_1069033] completed the study  if he/she has completed all periods of 
the study , including the last visit shown in the SoA .

PF-[ADDRESS_1069034] y:
Age and Sex:
1.Participants ≥18 y ears of age (or the minimum country -specific age of consent if >18) 
at the screening visit.
WOCBP may  be enrolled.
All fertile participants must agree to use a highl y effective method of 
contraception. Refer to Appendix 4 for reproductive criteria for male 
(Section 10.4.1) and female ( Section 10.4.2) participants.
Type of Participant and Disease Characteristics:
2.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures.
3.
Participants who have a negative screening SARS- CoV -[ADDRESS_1069035] result and 
who are as ymptomatic household contacts (ie, living in the same residence, see 
Appendix 13) of an individual who is sy mptomatic and recentl y tested positive for 
SARS -CoV -2 (ie, index case: patient with s ymptomatic COVID -19). To be included 
in the study , participants must be randomized within [ADDRESS_1069036] and within 96 hours of collection of the index case’s 
first positive SARS -CoV -[ADDRESS_1069037].  
Note: The index case will have confirmation of SARS- CoV -[ADDRESS_1069038] viral RNA or protein (see 
Section 8.1.5). 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 44Note: Participants with a negative screening SARS- CoV -[ADDRESS_1069039] 
result and whose baseline RT -
PCR result is returned as positive would be allowed to 
remain on treatment in the study .
Note: Asy mptomatic is defined as having no signs/sy mptoms consistent with 
COVID -[ADDRESS_1069040] 1 of the specified signs or 
symptoms consistent with COVID -19 (see Appendix 9 ).
Informed Consent: 
4.
Capable of giving signed informed consent as described in Appendix 1 , which 
includes compliance with the requirements and restrictions listed in the I CD and in 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.History  of SARS -CoV -[ADDRESS_1069041] (antibody , antigen, 
or nucleic acid) from an y specimen collected within 6 months before or during the 
screening visit.
2.Experiencing measured fever (documented temperature >38 ˚C or 100.4˚F) or other signs 
or sy mptoms consistent with COVI D-19 (see Appendix 9 ).
3.Known medical history  of active liver disease (other than nonalcoholic hepatic steatosis), 
including chronic or active hepatitis B or C infection, or primary  biliary  cirrhosis, 
ChildPugh Class B or C, or acute liver failure.
4.CKD or have known moderate to severe renal i
mpairment.
5.Known HIV infection with viral load >400 copi[INVESTIGATOR_014]/mL  within the last 6 months or taking 
prohibited medications for HIV treatment (from known medical history  within past 
6months of the screening visit) (see Appendix 8 ).
6.Suspected or confirmed concurrent active s ystemic infection that may  interfere with the 
evaluation of response to the study  intervention.
7.Active cancer requiring treatment, with prohibited medication (Appendix 8 ) that must be 
administered/continued during the trial period.
8.Any comorbidity  requiring hospi[INVESTIGATOR_5478]/or surgery  within 7 day s prior to study  
entry , or that is considered life -threatening within 30 day s prior to study  entry , as 
determi ned b y the investigator.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 459.Has h ypersensitivity  or other contraindication to any of the components of the study  
intervention, as determined by  [CONTACT_093]. 
10.Other medical or psy chiatric condition including recent (within the past year) or active 
suicida l ideation/behavior or laboratory  abnormality  that may  increase the risk of study  
participation or, in the investigator’s judgment , make the participant inappropriate for the 
study .
Prior/Concomitant Therapy:
11.Current or expected use of an y medications or substances that are highly  dependent on 
CYP3A4 for clearance and for which elevated plasma concentrations may be associated 
with serious and/or life -threatening events during treatment and for [ADDRESS_1069042] 
dose of PF -07321332/ritonavir (see Appendix 8 ).
12.Concomitant use of an y medications or substances that are strong inducers of CYP3A4 
are prohibited within [ADDRESS_1069043] dose of PF -07321332/ritonavir and during 
study  treatment (see Appendix 8 ).
13.Has received approved, authorized, or investigational anti -SARS -CoV -2 mAb, 
convalescent plasma, other drugs for treatment of COVID-19, or other anti- SARS -CoV -2 
biologic products within 6 months of screening . 
14.Has rec eived any  SARS -CoV -2 vaccine (includes any  level of vaccination) within 
6months prior to screening or is expected to receive a SARS -CoV -2 vaccine or other 
approved, authorized, or investigational postexposure proph ylaxis treatments through 
Day 38.
15.Is unwilling to abstain from participating in another interventional clinical study  with an 
investigational compound or device, including those for COVID -19 therapeutics, through 
the End of Study  visit.
Prior/Concurrent Clinical Study Experience:
16.Previous adm inistration with an investigational drug within 30 days (or as determined by  
[CONTACT_23606]) or [ADDRESS_1069044] dose of study  intervention used in 
this study  (whichever is longer).
17.
Known or prior participation in this trial or another trial involving PF -07321332.
Diagnostic Assessments:
18.Participants with known history  of any  of the following abnormalities in clinical 
laboratory  tests (within 6 months of the screening visit):
AST or ALT level 
≥2.[ADDRESS_1069045];

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 46Total bilirubin level ≥ [ADDRESS_1069046] ( ≥ 3X ULN for Gilbert ’ssyndrome );
eGFR <45 mL/min/1.73 m2within 6 months of the screening visit, using the serum 
creatinine -based CKD -EPI [INVESTIGATOR_14420]52
Absolute neutrophil count <1,000/mm3.
Note: If the investigator suspects the participant may  have any  of the above 
laboratory  values, confirmatory  tests should be performed at screening to confirm 
eligibility  before the first dose of study  intervention. See Appendix 2 for more details.
Other Exclusions:
19.Females who are pregnant or breastfeeding.
20.Investigator site staff or [COMPANY_007] employ ees directl y involved in the conduct of the study , 
site staff otherwise supervised by  [CONTACT_093], and their respective family  members. 
5.3.Lifestyle Considerations
5.3.1. Contraception
The investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contraception methods 
(seeAppendix 4 Section 
10.4.4) and will confirm that the participant has been instructed in 
its con
sistent and correct use. At time points indicated in the SoA, the investigator or 
designee will inform the participant of the need to use highl y effective contraception 
consistently  and correctly  and document the conversation and the participant’s affirmation in 
the participant’s chart (participants need to affirm their consistent and correct use of at least 1 
of the selected methods of contraception) considering that their risk for pregnancy  may  have 
changed since the last visit. I n addition, the investigator or designee will instruct the 
participant to call immediately  if the selected contraception method is discontinued or if 
pregnancy  is known or suspected in the participant or partner.
5.4.Screen Failures
Screen failures are defined a s participants who consent to participate in the clinical study  but 
are not subsequently  randomly  assigned to study  intervention. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to meet
the CONSORT publishing requirements and to respond to queries from regulatory  
authorities. Minimal information includes demography , screen failure details, eligibility  
criteria, and an y SAE.
Individuals who do not meet the criteria for participation in th
is study  (screen failure) may  
not be rescreened.  

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 475.5.Criteria for Temporarily Delaying Enrollment/Randomization/Administration of 
Study Intervention
Not applicable.
6.STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, medical device(s), or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, study  intervention refers to PF -07321332 15 0 mg tablets 
and matching placebo and ritonavir 100 mg capsules and matching placebo.
6.1.Study Intervention(s) Administered
Study Interventions(s)
Intervention Name [INVESTIGATOR_16335]-07321332 Placebo for 
PF-07321332Ritonavir Placebo for 
Ritonavir
ARM Nam e
(group of patients 
receiving a specific 
treatm ent (or no 
treatm ent)PF-07321332/ritonavir Placebo PF-07321332/ 
ritonavirPlacebo
Type drug placebo drug placebo
Dose Form ulation tablet tablet capsule capsule
Unit Dose Strength(s) 150 mg 0 mg 100 mg 0 mg
Dosage Level(s) 300 mg 0 mg 100 mg 0 mg 
Route of 
Administrationoral oral oral oral
Use experimental placebo experimental placebo
IMP or NIMP IMP IMP IMP IMP
Sourcing Provided centrally by 
[CONTACT_456].
Refer to the IP m anual.Provided 
centrally by 
[CONTACT_456].
Refer to the IP 
manual.Provided centrally by 
[CONTACT_456].
Refer to the IP 
manual.Provided 
centrally by 
[CONTACT_456].
Refer to the IP 
manual.
Packaging and 
LabelingStudy intervention will 
be provided in blister 
wallets. Each wallet 
will be labeled as Study 
intervention 
will be 
provided in Study intervention 
will be provided in 
HDPE bottles. Each 
bottle w ill be labeled Study 
intervention 
will be 
provided in 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 48Study Interventions(s)
required per country 
requirement. Products 
will be provided w ith 
blinded labels.blister w allets. 
Each wallet 
will be labeled 
as required per 
country 
requirement.as required per 
country requirement.HDPE bottles. 
Each bottle 
will be labeled 
as required 
per country 
requirement.
Current/Former 
Nam e(s) or Alias(es)PF-07321332 NA ritonavir NA
Study Arm(s)
Arm  Title PF-07321332/ritonavir 
(5-Day)Placebo PF-07321332/ritonavir 
(10-Day)
Arm  Type experimental placebo experimental 
Arm  Description Participants will receive 
PF-07321332/ritonavir 
300mg/100 mg q12h from 
Day 1 through Day 5 
followed by 0 mg/0 mg 
q12h from Day 6 through 
Day 10.Participants will receive 
0mg/0 mg q12h for 
10days from Day 1 
through Day 10.Participants will receive 
PF-07321332/ritonavir
300mg/100 mg q12h for 
10days from Day 1 
through Day 10.
Associated 
Intervention 
LabelsPF-07321332/ritonavir and 
Placebo for PF -07321332 
/Placebo for RitonavirPlacebo for PF -07321332 
and Placebo for RitonavirPF-07321332/ritonavir
6.1.1. Administration
PF-07321332 150 mg tablet or placebo for PF -07321332 will be administered with ritonavir 
100 mg or placebo for ritonavir capsule for 10 days. Participants will be dispensed:
2 tablets of PF- 07321332 150 mg or placebo for PF -07321332 (single tablet from 
each blister cell, one at a time) q12h
[ADDRESS_1069047] dose of stud y intervention on Day  1, preferably  during the 
in-person visit; that is, participants should take [ADDRESS_1069048] dose. The remaining doses should be taken every  12 
hours [±30 minutes]. Participants will swallow the study  intervention whole and will not 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 49manipulate or chew the study  intervention prior to swallowing. Participants may  take the 
study  intervention with or without food. Taking study  intervention with food may  improve 
tolerability . Refer to the IP Manual for additional dosing and administration instructions.
If a dose is delay ed, it should be taken as soon as possible, but no later than 4 hours before 
the next scheduled dose. Participants should not double up the next dose of study  
intervention in order to “make up” what had been missed. Dosing should be stopped at the 
endof the treatment period. Any  remaining tablets and/or capsules at the end of 10 day s (or 
11 day s if onl y one dose was administered on Day 1) should be returned.
6.2.Preparation, Handling, Storage, and Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  interventions received and any  
discrepancies are reported and resolved before use of the study  intervention. 
2.Only  participants e nrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. All study  
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) ar ea in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff. At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking day s must 
indicate the minimum and maximum temperatures since previousl y documented for 
all site storage locations upon return to business. Study  intervention may  be shipped 
by [CONTACT_778413]. [COMPANY_007] does not 
permit the shipment of study  intervention by  [CONTACT_2319]. The tracking record of shipments 
and the chain of custod y of study  intervention must be kept in the pa rticipant’s source 
documents/medical records. For investigational sites using ground transportation to 
deliver study  intervention to participants, stability data reveal that if the total duration 
of transit is less than [ADDRESS_1069049] participants on the proper storage requirements for take -home 
study  intervention.
7.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability , reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records), such as the 
IPAL or sponsor -approved equivalent. All study  interventions will be accounted for 
using a stud y intervention accountab ility form/record. All study  intervention that is 
taken home b y the participant, both used and unused, must be returned to the 
investigator b y the participant. Returned study intervention must not be redispensed 
to the participants.
8.Further guidance and in formation for the final disposition of unused study  
interventions are provided in the I P manual. All destruction must be adequately  
documented. If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the mater ials are destroy ed in compliance with 
applicable environmental regulations, institutional policy , and any  special instructions 
provided b y [COMPANY_007].
Upon identification of a product complaint, notify the sponsor within [ADDRESS_1069050] in the bottle and blister cards, as appropriate 
provided throughout the course of dosing and return the bottle and blister cards , as 
appropriate to the site at the next study  visit.
Study  intervention and placebo will be dispensed by  [CONTACT_295418]. The study  intervention will be administered in a blinded fashion 
to the participants.
Study intervention will be dispensed as noted in the SoA .
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study Intervention
Allocation of participants to treatment groups will proceed through the use of an IRT s ystem 
(IWR). The site personnel (study  coordinator or specified designee) will be required to enter 
or select information including but not limited to the user’s ID and password, the protocol 
number, and the participant number. The site personnel will then be provided with a 
treatment assignment, randomization number, and DU or container number when stud y 
intervention is being supplied via the I RT s ystem. The I RT sy stem will provide a 

PF-[ADDRESS_1069051] be stored in the site’s files. 
Study  intervention will be dispensed at the study  visit summarized in the SoA. 
Returned study  intervention must not be redispensed to the participants.
The study -specific I RT reference manual and I P manual will provide the contact [CONTACT_19974] s ystem.
6.3.2. Blinding of the Sponsor
The majority of sponsor staff will be blinded to study intervention allocation. There will be 
an unblinded team supporting the interactions with, and the anal yses for, the E -DMC while 
the study  is ongoing. The team will consist of clinicians, statistician(s), and programmer(s) 
and will be separate from the blinded members of the study  team.
The study  will be unblinded at the group and participant level after all participants complete 
the Day  38 visit (or ET prior to Day  38 visit). However, if efficacy  is demonstrated at the 
interim analysis, an unblinded submissions team ma y be assembled to prepare unblinded 
analyses and documents to support regulatory  activities that may  be required while the study  
is ongoing.
Details of the unblinded sponsor staff supporting the E -DMC and the timing of unblinding 
will be outlined in the U nblinding Plan.
6.3.3. Breaking the Blind 
The I RT will be programmed with blind -breaking instructions. I n case of an emergency , the 
investigator has the sole responsibility  for determining if unblinding of a participant’s 
treatment assignment is warranted. Parti cipant safety  must alway s be the first consideration 
in making such a determination. If the investigator decides that unblinding is warranted, the 
investigator should make every  effort to contact [CONTACT_1152] a 
participant’s treatment as signment unless this could delay  further management of the 
participant. If a participant’s treatment assignment is unblinded, the sponsor must be notified 
within [ADDRESS_1069052] information 
and further details on the use of the IRT s ystem.
6.4. Study Intervention Compliance
Participants will be issued an electronic study  intervention diary  (ie, participant -completed 
study  intervention log) or may  use an application installed on their device and will be 
educated to record the date and time of their stud y intervention dosing preferabl y at the time 
of first dose.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 52Compliance with study  intervention will be assessed by  [CONTACT_295419], review 
of the electronic study  intervention diary , and discussion with the partic ipant.
Study  intervention administration, including any  deviation(s) from the prescribed dosage 
regimen, should be recorded in the CRF.
A record of the number of study  intervention tablets/capsules dispensed to and taken by  [CONTACT_778414]. Intervention start and stop dates, including dates for intervention delay s and/or dose 
reductions, will also be recorded in the CRF.
The following noncompliance cases will be considered med ication errors 
(See Section 8.3.10):
Participants interrupting study  intervention for 2 consecutive doses;
Participants taking either PF-07321332 or ritonavir alone for 2 consecutive doses.
Participants who have an overall study  intervention compliance of <80% or >115%. 
In addition to the above -listed medication errors, any  deviation from protocol -specified 
dosing (eg, missed single dose or partial dose) should be recorded as a protocol deviation and 
the investigator or designee is to counsel the participant and ensure steps are taken to 
improve compliance.
6.5.Dose Modification 
Dose modification for PF -
07321332/ritonavir is not allowed.
6.6.Continued Access to Study Intervention After the End of the Study
No intervention will be provided to study  participants at the end of their study  participation.
6.7.Treatment of Overdose
For this study , any  dose of PF -07321332 greater than 900 mg or ritonavir greater than 
300mg within a 24 -hour time period will be considered an overdose.
There is no specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact [CONTACT_22840] 24 hours.
2.Closely  monitor the particip ant for an y AEs/SAEs and laboratory  abnormalities for at 
least 5 half -lives or 28 calendar day s after the overdose of study  intervention 
(whichever is longer).

PF-[ADDRESS_1069053] dose of 
study  intervention if requested by  [CONTACT_7195] (determined on a case -by-case 
basis).
Decisi ons regarding dose interruptions or modifications will be made by  [CONTACT_78256].   
6.8.Concomitant Therapy
Hormonal contraceptives that meet the requirements of thi s study  are allowed to be used in 
participants who are WOCBP (see Appendix 4 ).
Permitted During the Study
All participants who develop confirmed COVID -19 may  continue study  intervention and 
may receive SoC therapy including 
products authorized under an Emergency  Use 
Authorization (or equivalent in countries where the study  is being conducted) where 
appropriate , in addition to study  intervention, unless listed as prohibited medication (see 
below and Appendix 8 ). Discontinuation of study  intervention is at the investigator’s 
discretion. However, if the investigator de cides to administer SoC therapy  for COVID
-[ADDRESS_1069054] discontinue study  intervention but 
should continue in the study . SoC therap y is defined as an y therap y that is approved and used 
as indicated b y the local regulatory  authorities (including approvals for emergency  use, 
compassionate use, or through similar regulatory  guidance), or any  therapy  as recommended 
by a relevant national (or a reputable international) scientific body  (eg, WHO, ECDC, CDC, 
NIH). Sites should consult with the sponsor if a new SoC option becomes available after 
study  initiation. The investigator should ensure that an y recommended SoC therap y is not a 
strong inducer of CYP3A4 or highl y dependent on CYP3A4 for clearance if it is planned to
be administered concomitantly  with study  intervention.
In countries in which therapi[INVESTIGATOR_778372] -
19,all participants who develop confirmed COVID -19 disease will be referred 
locally  for treatment as deemed appropriate by [CONTACT_093] (see above) and local 
guidelines. This referral should be documented. Notwithstanding, this treatment is not 
mandatory  for participation in this study .
Prohibited During the Study
Participants may  not receive therapeutics, drugs, or vaccines described in the exclusion 
criteria (see Section 5.2), antiviral treatment for COVID -19 (eg, molnupi[INVESTIGATOR_42654], Paxlovid) or 
listed as prohibited medications (see Appendix 8 ) during the stud y period with the exceptions
described above for participants who develop confirmed COVID -
19.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 54PF-07321332 and ritonavir are both primarily  metab olized by  [CONTACT_9058] P450 (CYP) 3A4. 
Therefore, concomitant use of an y medications or substances that are strong inducers of 
CYP3A4 are prohibited within 28 day s prior to dosing of study  intervention and during study  
treatment.
Additionally , PF-07321332 and ritonavir are inhibitors of CYP3A4. Therefore, medications 
highl y dependent on CYP3A4 for clearance and for which elevated plasma concentrations 
may be associated with serious and/or life- threatening events are not permitted during dosing 
of PF -07321332/ ritonavir and for [ADDRESS_1069055] dose of PF -07321332/ritonavir. 
Because ritonavir [ADDRESS_1069056] medical supportive care may  be provid ed to manage AEs.
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
It may  be necessary  for a participant to permanently  discontinue study  intervention. Reasons 
for permanent discontinuation of study  intervention include the following:
AE (including Grade 3 severity  or greater and considered by  [CONTACT_319422] y intervention);
SAE considered b y the investigator to be related to the study intervention;
Requirement for prohibited concomitant medication;
Death;
Pregnancy ; 
Study  terminated by  [CONTACT_3211];
Withdrawal by  [CONTACT_3445];
Hospi[INVESTIGATOR_778373];

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 55Miss more than [ADDRESS_1069057] be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of stud y intervention or also from study  procedures, posttreatment study  follow -up, 
and/or future collection of additional information.
7.1.1. Potential Cases of Decreased eGFR
If postcreening eGFR is <45 mL /min/1.73m2, the participant will be instructed to discontinue 
any remaining study  intervention doses as soon as study  staff become aware of laboratory  
results.
7.2.Participant Discontinuation/Withdrawal From the Study 
A participant may withdraw from the stud y at an y time at his/her own request. Reasons for 
discontinuation from the study  include the following:
Refused further stud y procedures;
Lost to follow -up;
Death;
Study  terminated by  [CONTACT_3211];
At the time of discontinuing from the stud y, if p ossible, an earl y discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study  
discontinuation and follow up and for an y further evaluations that need to be completed. 
The early  discont inuation visit applies only  to participants who are enrolled/randomized and 
then are prematurely  withdrawn from the study . Participants should be questioned regarding 
their reason for withdrawal.  
If a participant withdraws from the study , he/she may  requ est destruction of an y remaining 
samples taken and not tested, and the investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdraws consent (see Se ction 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 

PF-[ADDRESS_1069058] 
with him or her or persons previously  authorized by  [CONTACT_19983]. Participants s hould notify  the investigator in writing of the decision to withdraw 
consent from future follow up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical records b y the investigator, as to whether the withdrawal is 
only from further receipt of study  intervention or also from study  procedures and/or 
posttreatment study  follow up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly  available 
information should be used to determine vital status only  as appropriatel y directed in 
accordance with local law.
7.3.Lost to Follow -Up 
A participant will be considered lost to follow
-up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contact[INVESTIGATOR_530] b y the study  site.
The following actions must be taken if a participant fails to be available for a required stud y 
visit:
The site must attempt to contact [CONTACT_14315]. Couns el the participant on the importance of maintaining the 
assigned visit schedule, and ascertain whether the participant wishes to and/or should 
continue in the study ;
Before a participant is deemed lost to follow-up, the investigator or designee must 
make e very effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_778415]’s medical record;
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.

PF-[ADDRESS_1069059] reasons for 
screening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICD may be utilized for screening or baseline 
purposes provided the procedures met the protocol -specified criteria and were performed 
within the time frame defined in the SoA.
In the event a participant is hospi[INVESTIGATOR_057], study  assessments should be performed as feasible. 
Procedures not per formed due to hospi[INVESTIGATOR_778374].
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may  be 
circums tances outside the control of the investigator that may  make it unfeasible to perform 
the test. I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant. When a protocol-required test cannot be p erformed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incide nts in a timely  manner.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_19987] .
The total blood sampling volume for individual participants in this study  is approximately  
[ADDRESS_1069060] an optional PK sample (Tasso device). The actual 
collection times of blood sampling may  change. Additional blood samples may  be taken for 
safet y assessments at times specified b y [COMPANY_007], provided the total volume taken during the 
study  does not exceed [ADDRESS_1069061] daily  COVID -19 signs and s ymptoms, study  intervention administration, 
and PRO assessments in the stud y diar y. 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 58Participants will receive daily  reminders to complete entries on their own as specified in the 
SoA. The diary  should be completed at approximately  the same time every day . Staff will 
review the participant’s study  diary  online as specified in the SoA.
The diary  allows recording of these assessments only  within a fixed time window (eg, 24h), 
thus providing an accurate representation of the participant’s experience at that time. The 
participant is able t o make revisions to incorrect entries before pressing the save or submit 
button. I n the event that a participant becomes aware of an error in data after the entry  is 
saved, a change to the diary  data may  only be made by  [CONTACT_295422] a data 
clarification form. Data reported in the participant diary  will be transferred electronically  to a 
third- party vendor, where they will be available for review b y investigators and the sponsor 
or delegate at all times via an internet -based portal.
8.1.2. Daily Sign s and Symptoms of COVID -19
On Day  1, participants will complete the study  diary  before receiving study intervention. 
Participant assessment of COVID -19-related s ymptoms should be recorded at approximately  
the same time each day  as specified in the SoA and as described in 
Section 8.1.1.
COVID -19-related s ymptoms will be evaluated in accordance with FDA guidelines 
(Appendix 9 ).53Participants w ill record a dail y severity rating of their s ymptoms  over the 
past 24 hours based on a 4
-point scale in which 0 is reported if no s ymptoms were present; 1 
if mild; 2 if moderate; and 3 if severe. 
Vomiting and diarrhea will each be rated on a 4 -point frequency  scale where 0 is reported for 
no occurrence, 1 for 1 to 2 times, 2 for 3 to 4 times, and 3 for 5 or greater. 
Sense of smell and sense of taste will each be rated on a 3- point L ikert scale where 0 is 
reported if the sense of smell/taste was the same as usual, 1 if the sense of smell/taste was 
less than usual, and 2 for no sense of smell/taste. Investigators will instruct participants to 
contact [CONTACT_778416]/sy mptoms of COVID-19 – to inform them of their 
symptoms and to schedule a COVID
-19 Signs/S ymptoms Onset visit as soon as possible, but 
no later than [ADDRESS_1069062] 
symptomatic participants to follow local public health measures to reduce the spread of 
COVID -
19.
8.1.3. COVID -19 Related Medical Visit Details
Details of participants’ COVID -19-related medical visits (ie, hospi[INVESTIGATOR_059], practitioner’s
office, home healthcare services, telemedicine, urgent care, emergency  room ≤24h, 
extended care facility  stay) will be collected during study  visits, including level of care 
(ICUstatus) and dates of utilization, including admission and discharge, as applicable. 
If the participant has a COVID -19 Signs/Sy mptoms Onset visit, this must be reported as a 
COVID -19 rel ated medical visit.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 59Hospi[INVESTIGATOR_31561] >24h of acute care, in a hospi[INVESTIGATOR_419781] , 
including Emergency  Rooms or temporary  facilities instituted to address medical needs of 
those with severe COVID -19 during the COVID -19 pandemic. This includes specialized 
acute medical care unit within an assisted living facility  or nursing home. This does not 
include hospi[INVESTIGATOR_778375].
8.1.4. Oxygen Support Details
Type of oxy gen support (e g, ox ygen supplementation received at home, mechanical 
ventilation received in hospi[INVESTIGATOR_307]) will be collected.
8.1.5. Index Case Characteristics
Index cases will be determined through interview with the C4671006 study  participant. The 
index case may  be a participant in the C4671002 or C4671005 studies, but this is not 
required. However, minimum data as outlined below must be collected for confirmation of 
the C4671006 study  participant’s status as a household contact [CONTACT_778417].
The following information about the index case will be collected through interview with the 
study  participant: 
Date of index case SARS -CoV -2 infection diagnosis (sample collection date of first 
positive test);
Date of onset of COVID -19 sy mptoms.
The following information about the index case will be collected through interview with the 
study  participant to characterize the exposure period. For index cases who are participants in 
the C4671002 or C4671005 study , this information will be collected in those studies. If the 
index case i s not a participant in the C4671002 or C4671005 study , this information will only  
be collected if available and permitted by  [CONTACT_10976]:
Age; 
Whether the index case received vaccination or treatment for COVID -19 prior to or 
during the expo sure period;
Whether the index case was isolated from the study  participant after the initial 
exposure;
Relationship of the index case to the stud y participant (spouse, parent, son/daughter, 
etc);
Does the index case sleep in the same room as the study  participant.

PF-07321332
Protocol C4671006Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 608.1.6. Household Characteristics 
Household characteristics will be determined through interview with the C4671006 study 
participant and may be updated during the study. This assessment will support the characterization of the exposure period and may be relevant for interpretation of efficacy data. The household characteristics include:
•Number of people living in household;
•Number of additional confirmed SARS-CoV positive or suspected (ie, symptomatic) 
household members;
•Number of other household contacts in this residence who are participants in this 
study or receiving another COVID-19 treatment.
8.1.7. PRO Assessments
[IP_ADDRESS]. WPAICOVID-19 impacts manual and office-based work, and results in missed work due to illness 
or quarantine and loss in productivity.
54The WPAI-GH is being implemented for COVID-19 
(ie, WPAI-COVID-19) in order to evaluate change from baseline in work burdens. The WPAI-GH has demonstrated validity, reliability and sufficient predictive value to measure the impact of disease on absenteeism, presenteeism, and overall productivity in a manner that can also be monetized.
55
 
 
 
 
 
 
 
[IP_ADDRESS]. EQ-5D-5L Scale
The EQ-5D is a validated, standardized, generic instrument that is a preference-based health 
related quality of life questionnaire in cost effectiveness and HTA.56-58Recently, a version 
was developed called EQ-5D-5L with 5 response levels on each dimension.56-62
Measurement properties of the EQ-5D-5L demonstrated to be a valid version of the 3 level questionnaire that improved measurements by [CONTACT_770451], reducing the ceiling, and establishing convergent and known groups validity.
56,58,60,61Both the EuroQol 
EQ-5D-3L and EQ-5D-5L versions are well established instruments used to measure health CCI
PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 61states and utilities in various diseases areas and assess mobility , self care, usual activities, 
pain/discomfort, anxiety /depression and health status using a VAS.59,63The EQ-5D- 5L 
should be completed as described in the SoA.
[IP_ADDRESS]. Global Impression Questions
For participants who report COVID -19 s ymptoms in the diary , 3 additional questions will be 
included in the ePRO to assess patient -
reported global impression items: a) return to usual 
health; b) return to usual activities; and c) overall COVID-19- related s ymptoms.53
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the 
SoA.Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.
8.2.1. Medical History
Medical history  (including prior documented infection) and demographics will be collected 
at screening. Smoking status will be collected. Complete medication history  of all 
prescription or nonprescription drugs (including vaccinations), and dietary  and herbal 
supplements taken within [ADDRESS_1069063] dose will be collected.
Risk factors for the study participant developi[INVESTIGATOR_21337] -19 illness will be recorded 
(Appendix 11).
8.2.2. Height and Weight
Height and weight will also be measured and recorded at screening. Height may  be self -
reported.
8.2.3. Targeted Physical Examinations
A targeted ph ysical examination will include, at a minimum, cardiopulmonary  assessments. 
Investigators should pay  special attention to any  previously  identified or new AE/targeted 
condition that the participant has experienced.
Physical examination findings collected during the study  will be considered source data and 
will not be required to be reported, unless otherwise noted. An y untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE ( Appendix 3 ) must be reported according to the processes in 
Sections 8.3.1 to 8.3.3.
8.2.4. Vital Signs
Temperature, pulse rate, respi[INVESTIGATOR_2842], and blood pressure will be assessed as specified in 
the 
SoA. In addition to this, participants at tending a COVID -19 Signs/Sy mptoms Onset visit 
will also have ox ygen saturation measured.

PF-[ADDRESS_1069064] 
for the participant in a quiet setting without distractions (eg, television, cell phones).
Investigators will supply  each participant with a thermometer and will instruct them to 
measure their temperature if they are feeling feverish. I nvestigators will instruct participants 
to contact [CONTACT_778418] a fever (>100.4°F or >38°C), to inform them of their fever and 
to schedule a COVID -19 Signs/Sy mptoms Onset visit as soon as possible but no later than 
2days after symptom onset, as specified in the SoA . Investigators will instruct participants 
with fever to follow local public health measures to reduce the spread of COVID -
19.
Each participant will also be supplied with a pulse oximeter to be used at home as directed b y 
the investigator. This may include monitoring of ox ygen saturation for participants who 
develop COVID -[ADDRESS_1069065] be conducted in accordance with the laboratory  manual and the SoA. 
Unscheduled clinical laboratory  measurements may  be obtained at any  time during the study  
to assess an y perceived safet y issues.  
Laboratory  safet y parameters will be graded according to the Division of AIDS (DAIDS) 
Table for Grading the Severity of Adult and Pediatric Adverse Events,64version 2.1. The 
investigator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study  in the AE section of the CRF. 
Clinically  significant abnormal lab oratory  findings are those which are not associated with 
the underl ying disease, unless judged by  [CONTACT_78259]'s condition.
If a baseline laboratory  result meets Section 5.[ADDRESS_1069066] dose of study  intervention should be 
repeated until the values return to normal or baseline or are no longer considered clinically  
significant b y the investigat or or medical monitor.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 63If such values do not return to normal/baseline within a period of time judged reasonable by  
[CONTACT_093], the etiology  should be identified and the sponsor notified.
See Appendix [ADDRESS_1069067] 
25mIU/mL. Pregnancy  tests will be performed in WOCBP at the times listed in the SoA. 
Following a negative pregnancy  test result at screening, appropriate contraception must be 
commenced. Pregnancy  tests will also be done whenever 1 menstrual cy cle is missed during 
the active treatment period (or when potential pregnancy  is otherwise suspected) and at the 
end of the stud y. Pregnancy tests may also be repeated if requested b y IRBs/ECs or if 
required b y local regulations. If a urine test cannot be confirmed as negative (eg, an 
ambiguous result), a serum pregnancy  test is required. In such cases, the participant must be 
excluded if the serum pregnancy  result is positive.
If a participant requiring pregnancy  testing cannot visit a local laboratory , a home urine 
pregnancy testing kit with a sensitivi ty of at least 25 mI U/mL may  be used by  [CONTACT_295423], if compliant with local regulatory  requirements. The pregnancy  
test outcome should be documented in the participant’s source documents/medical records. If 
the pregnancy  test is positive, the EDP should be reported ( Section [IP_ADDRESS]). Confirm that the 
participant is adhering to the contraception method(s) required in the protocol.
8.3.
Adverse Events, Serious Adverse Events, and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3 .
AEs may  arise from s ymptoms or other complaints reported to the investigator by  [CONTACT_2416] (or, when appropriate, b y a caregiver, surrogate, or the participant's legall y 
authorized representative), or they  may  arise from clinical findings of the Investigator or 
other healthcare providers (clinical signs, tes t results, etc.).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study  intervention (see Section 7.1). 
During the active collection period as described in Section 
8.3.1, each participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -up 
information in an expedited fashion.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 648.3.1. Time Period and Frequency for Collecting AE and SAE Information
Thetime period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant’s participation in the study  (ie, bef ore undergoing 
any study -related procedure and/or receiving study  intervention), through and including a 
minimum of [ADDRESS_1069068] SAE Report Form.
Investigators are not obligated to activel y seek information on AEs or SAEs after the 
participant has conc luded study  participation . However, if the investigator learns of an y SAE, 
including a death, at an y time after a participant has completed the stud y, and he/she 
considers the event to be reasonabl y related to the study  intervention, the investigator must 
promptly  report the SAE to [COMPANY_007] using the CT SAE Report Form.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.[ADDRESS_1069069] SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24
hours of it being available.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins af ter obtaining informed consent as described in Section 8.3.[ADDRESS_1069070] on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  [CONTACT_2299].

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 658.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AEs and SAEs and the 
procedures for completing and transmitting SAE reports a re provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurren ces.
8.3.3. Follow -Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively  follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolut ion, stabilization, the event is otherwise explained, 
or the participant is lost to follow
-up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality . Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary  of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety . 
Further information on follow -up procedures is given in Appendix [ADDRESS_1069071] the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs , and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]Rs according to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives S[LOCATION_003]Rs or other specific safet y information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study  and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure, occurs when a person not enrolled in the study  as a participant 
receives unplanned direct contact [CONTACT_216480]. Such exposure 
may or may  not lead to the occurrence of an AE or SAE. Persons at risk for environmental 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 66exposure i nclude healthcare providers, famil y members, and others who may be exposed. An 
environmental exposure may  include exposure during pregnancy , exposure during 
breastfeeding, and occupational exposure.
Any such exposure to the study  intervention under study  are reportable to [COMPANY_007] Safet y 
within 24 hours of investigator awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if: 
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention. 
A male participant who is receiv ing or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception.
A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure. Below are examples of 
environmental EDP:  
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  [CONTACT_78262].
A male famil y member or healthcare provider who has been exposed to the study 
intervention by  [CONTACT_78263].
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initia l information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to [COMPANY_007] Safety  on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until a minimum 
of [ADDRESS_1069072] administration of study  intervention.
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the partic ipant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 67Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to the initial EDP Supplemental Form. In the case of a live birth , the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assesse d by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ecto pic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting S AEs. Additional information about pregnancy outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 
Spontaneous abortion including miscarriage and missed abortion;
Neonatal deaths that occur within [ADDRESS_1069073] 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested b y the sponsor. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paternal exposure, the 
investigator will provide the participant wit h the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention.
A female is found to be breastfeeding while being exposed or having been exposed to 
study intervention (ie, environmental exposure). An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by [CONTACT_78262].

PF-[ADDRESS_1069074] report exposure during breastfeeding to [COMPANY_007] Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occurs in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the study , so the information is not recorded on a 
CRF. However, a cop y of the completed CT SAE Report Form is maintained in the 
investigator site file.
An exposure during breastfeeding report is not created when a [COMPANY_007] drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences a n SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
The investigator must report any  instance of occupational exposure to [COMPANY_007] Safet y within 
24 hours of the investigator’s awarenes s using the CT SAE Report Form, regardless of 
whether there is an associated SAE. Since the information about the occupational exposure 
does not pertain to a participant enrolled in the study , the information is not recorded on a 
CRF; however, a cop y of th e completed CT SAE Report Form must be maintained in the 
investigator site file.
8.3.6. Cardiovascular and Death Events
Not applicable.
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.3.8. Adverse Events of Special Interest
AESI s include hemody namic events, inflammatory  events, and thy roid- related events.
Adverse events of special interest (AESIs) are examined as part of routine safet y data review 
procedures throughout the clinical trial and as part of signal detecti on processes.
All AESI s must be reported as an AE or SAE following the procedures described in 
Sections 8.3.[ADDRESS_1069075] SAE Report Form. 
[IP_ADDRESS]. Lack of Efficacy
The investigator must report signs, s ymptoms, and/or clinical sequelae resulting from lack of 
efficacy . Lack of efficacy  or failure of expected pharmacological action is reportable to 
[COMPANY_007] Safety  only if associated with an SAE .  

PF-[ADDRESS_1069076] SAE Report 
Form to [COMPANY_007] Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study  participant.
The administration of expi[INVESTIGATOR_214312]
The administration of an incorrect study  intervention
The administration of an incorrect dosage
The administration of study  intervention that has undergone temperature excursion 
from the specifi ed storage range, unless it is determined by  [CONTACT_214348]
The administration of study  intervention consistent with the medication error 
descriptions in Section 6.4.
Such medication errors occurring to a stud
y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours.
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 

PF-07321332
Protocol C4671006Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 70applicable, any associated AE(s), serious and nonserious, are recorded on the AE page of the 
CRF.
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_1069077] SAE Report 
Form only when associated with an SAE.
8.4. Pharmacokinetics
Blood samples of approximately 4 mL, to provide a minimum of 2 mL plasma, will be 
collected for measurement of plasma concentrations of PF-07321332 as specified in the SoA. 
Self-collected whole blood (Tasso device) may also be collected and used to measure concentrations of PF-07321332. Instructions for the collection and handling of biological samples will be provided in the laboratory manual or by [CONTACT_456]. The actual date and time (24-hour clock time) of each sample will be recorded.
The actual times may change, but the number of samples will remain the same. All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing. Collection ofsamples obtained ≤[ADDRESS_1069078] time of the collection is noted on the source document and the CRF. This protocol deviation window does not apply to samples to be collected more than 10 hours after dose administration at outpatient/follow-up visits with visit windows.
Samples will be used to evaluate the PK of PF-07321332. Samples collected for analyses of 
PF-07321332 concentration may also be used to evaluate safety or efficacy aspects related to concerns arising during or after the study, for metabolite identification and/or evaluation of the bioanalytical method, or for research related to the study intervention(s) and COVID-19. Samples may also be used to evaluate the PK of ritonavir.
Genetic analyses will not be performed on these samples unless consent for this was included 
in the informed consent. Participant confidentiality will be maintained.
Samples collected for measurement of concentrations of PF-[ADDRESS_1069079] be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity. Any deviations from the PK sample 
handling procedure (eg, sample collection and processing steps, interim storage or shippi[INVESTIGATOR_15889]), including any actions taken, must be documented and reported to the sponsor. On a case-by-case basis, the sponsor may make a determination as to whether sample integrity has been compromised.
Drug concentration information that would unblind the study will not be reported to 
investigator sites or blinded personnel until the study has been unblinded.CCICCI
PF-[ADDRESS_1069080] 
be documented and approved by [CONTACT_487229], but will not constitute a protocol amendment. The IRB/EC will be informed of any safety issues that require alteration of the safety monitoring scheme or amendment of the ICD.
8.6. Biomarkers
Collection of samples for biomarker research is also part of this study. 
The following samples for biomarker research are required and will be collected from all 
participants in this study as specified in the SoA:
•Nasal swab will be collected to measure SARS CoV-2 viral load by [CONTACT_937]-PCR. 
•Nasal viral load samples may be used for SARS CoV-2 viral sequencing.
•Nasal viral load samples may be used for SARS CoV-2 infectivity assays and 
phenotypic analyses. 
•10 mL blood optimized for plasma may be utilized for proteomics and immunologic 
studies.
8.6.1. Specified Gene Expression (RNA) Research
Specified gene expression (RNA) research is not included in this study.
8.6.2. Specified Protein Research 
Blood will be collected for plasma biomarkers as specified in the SoA and may be used for 
proteomics, immunologic studies, as well as markers associated with coagulation, organ or CCI
CCI
PF-07321332
Protocol C4671006Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 72endothelial cell dysfunction. Storage and shippi[INVESTIGATOR_778376].
8.6.3. Specified Metabolomic Research
Specified metabolomic research is not included in this study.
8.6.4. SARS-CoV-2 Assessments
[IP_ADDRESS]. Rapid Antigen AssessmentsRapid antigen testing for SARS-CoV-[ADDRESS_1069081] kits that are authorized for use in this study.
[IP_ADDRESS]. Viral Load Assessments
The first nasal swab will be self collected by [CONTACT_778419]. Thereafter, nasal swabs will be collected by [CONTACT_778420]. On the days where there is an in-
person visit, the nasal swab should be collected by [CONTACT_778421]. If, for any reason, a nasal swab was already collected in the morning of an in person visit, another swab for viral load assessment should not be collected on the same day and that would not be considered a protocol deviation.
Additional swabs may be required at the visit on days for which an in-person visit occurs (eg, 
COVID-19 Signs/Symptoms Onset visit), which should be collected by [CONTACT_778422]. 
Results of centrally read nasal swabs will not be available to the investigator. Therefore if 
COVID-19 symptoms occur during the study, investigators will make treatment decisions based on assessment of the participant’s symptoms, rapid antigen testing results, other locally available testing results (eg, RT-PCR) obtained and used outside this trial, and other relevant factors determined in the investigator’s clinical judgment. Results of these local tests will be recorded on the CRF.
Nasal swabs will be collected per the SoA, and may be analyzed to measure SARS-CoV-[ADDRESS_1069082] of care. Results of these tests will be 
recorded in the CRF.
8.6.6. Retained Research Samples for Biomarkers
These Retained Research Samples will be collected in this study :
10 mL  blood optimized for serum isolation Prep B2
Retained Research Samples will be collected as local regulations and IRB/ECs allow 
according to the SoA .  
Retained Research Samples may  be used for research related to the study  intervention(s) and 
COVID -19. Genes and other anal ytes (eg, proteins, RNA, nondrug metabolites) may  be 
studied using the retained samples. 
See Appendix 5 for information regarding genetic research. Details on processes for 
collection and shipment of these sa mples can be found in the laboratory  manual. 
8.7.Immunogenicity Assessments
Immunogenicit y assessments are not included in this study .
8.8.Health Economics
Health economics/medical resource utilization and health economics parameters will be 
evaluated in this stu dy (Section 8.1.2. and Section 8.1.3).
9.STATISTICAL CONSIDER
ATIONS
Detailed methodolo gy for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in a SAP, which will be maintained b y the sponsor. The 
SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses will also be reflected in a 
protocol amendment.
9.1.Statistical Hypotheses
The primary  hypothesis is to test, in participants who have a negative RT -PCR at baseline, 
whether or not the risk rat io between 5- day and 10 -day regimens of PF -07321332/ritonavir 

PF-[ADDRESS_1069083]-confirmed infection through Day 14 is equal to 1:
Null hypothesis:  H 0    గುಷషబళయమభభయయమ
గ೛೗ೌ೎೐್೚ൌ1           
Alternative hypothesis: H a    గುಷషబళయమభభయయమ
గ೛೗ೌ೎೐್೚്1          
Where πPF-07321332 versusπplacebo are the symptomatic infection rate through Day 14 for 
5-day and 10-day regimens of PF-07321332 /ritonavir versus placebo groups in participants who have a negative RT-PCR result at baseline.
9.1.1. Estimands
[IP_ADDRESS]. Primary Estimand/Co-Primary EstimandsThe primary estimand is the risk reduction between 5-day and 10-day regimens of 
PF-07321332/ritonavir versus placebo in the proportion of individuals who develop symptomatic RT-PCR or rapid antigen test-confirmed SARS-CoV-[ADDRESS_1069084] to adherence to randomized treatment.
[IP_ADDRESS]. Secondary Estimand
The estimand associated with the secondary objective is  
•The risk reduction between 5-day and 10-day regimens of PF-07321332/ritonavir versus 
placebo in the proportion of individuals who develop symptomatic RT-PCR or rapid antigen test-confirmed SARS CoV-[ADDRESS_1069085]-confirmed infection through Day 14 is 
considered the main clinical outcome measure so estimands for the measure in targeted populations are presented. Estimands for the other outcome measures/populations are considered supportive of the main outcome measures and are not presented.
9.1.2. Multiplicity Adjustment
There will be 2 group comparisons for the primary endpoint: 5-day regimen of 
PF-07321332/ritonavir versus placebo groups and 10-day regimen of PF-07321332/ritonavir versus placebo groups. Multiplicity adjustment for the primary endpoint will be made for multiple comparisons using Hochberg method.
[ADDRESS_1069086] of the primary endpoint, the key secondary endpoint will be tested sequentially: proportion of participants with symptomatic RT-PCR or rapid antigen 
PF-[ADDRESS_1069087] for multiple comparisons 
for both treatment groups.
If one of PF -07321332/ritonavir arms is discontinued, sequential testing will be performed in 
the remaining PF -07321332/ritonavir arm in the order of primary  endpoint and the ke y 
secondary  endpoint. Details will be provided in the SAP or interim anal ysis plan.
9.2.Analysis Sets
For purposes of analy sis, the following anal ysis sets are defined:
Participant Analysis Set Description
Full Anal ysis Set (FAS) All participants randomly  assigned to study  intervention.
Safety  Anal ysis Set All participants randomly  assigned to study  intervention 
and who take at least 1 dose of study  intervention. 
Participants will be anal yzed according to the study 
intervention they  received.
Modified Intent -To-Treat
(mITT)All participants randomly  assigned to study  intervention 
who take at least [ADDRESS_1069088] a 
negative RT -PCR result at baseline .  
Participants will be anal yzed according to the study 
intervention they  were randomized.
Modified Intent -To-
Treat1 (mITT1)All participants randomly  assigned to study  intervention 
who take at least [ADDRESS_1069089] a 
positive RT -PCR result at baseline.  
Participants will be anal yzed according to the study 
intervention they  were randomized.
Modified Intent -To-
Treat2 (mITT2)All participants randomly  assigned to study  intervention 
who take at least [ADDRESS_1069090] a 
negative RT -PCR result at baseline and are at increased 
risk of severe COV ID-19 illness.
Participants will be anal yzed according to the study 
intervention they  were randomized.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 76Participant Analysis Set Description
Per-Protocol (PP) All participants in the mITT set without important protocol 
deviations considered to impact the interpretation of the 
primary  efficacy endpoint. Protocol deviations will be 
reviewed to generate the list of participants with significant 
deviations to be excluded from the PP analy sis set. The PP 
exclusion criteria will be finalized prior to breaking the 
blind.
9.3. Statistical Analyses
The SA P will be developed and finalized before any  anal yses are performed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data. 
This section is a summary of the planned statistical analy ses of the primary  and second ary 
endpoints.
9.3.1. General Considerations
The number of participants randomized to the double -blind treatment phase , completing the 
study  drug administration, and completing the study  will be summarized from the FAS. The 
reason for discontinuations will be sum marized by [CONTACT_1570]. 
Baseline demographic and other characteristics will be tabulated for the FAS and 
summarized by  [CONTACT_1570]. Quantitative variables will be described by  [CONTACT_312589] (mean, standard deviation, minimum, and maximum), and qualitative 
variables will be summarized by  [CONTACT_295424] .
For continuous endpoints, an MMRM or ANCOVA model will be used to anal yze change 
from baseline, whichever is appropriate. Estimated mean differences between treatments 
groups will be calculated.
For categorical endpoints, proportion of participants for each category  will be summarized 
for each group.
For count endpoints, the total number of the events and average number of events will be 
summarized for each group. 
Time to event will be summarized graphicall y using Kaplan -Meier plots for each of the 
treatment groups. Treatment comparisons will be conducted using Cox proportional hazard 
model .

PF-[ADDRESS_1069091] confirming SARS- CoV -2 
infection in anal yses of the primary  and relevant secondary  endpoints.  
the first instance of a positive RT -PCR with either a positive or negative rapid antigen 
test, or
the first instance of a positive rapid antigen test with a negative RT -PCR test.
If only  [ADDRESS_1069092] is available, infection is defined as a positive result (RT -PCR or rapid antigen 
test).
Considering the frequency (daily  Day s 1-14 and at COVID -19 signs and s ymptoms onset 
visits) and greater sensitivity  for RT -PCR testing relative to the rapid antigen test, it is 
anticipated that the majority  of primary  endpoint events will be confirmed with a positive 
RT-PCR result .
9.3.2. Primary Endpoint(s)/Estimand(s) Analysis
The primary  efficacy  analy sis will be conducted using the mITT anal ysis set. 
For the primary  efficacy  anal ysis, GEE will be used to anal yze the proportion of participants 
with a negative RT -PCR result at baseline who develop a s ymptomatic RT -PCR or rapid 
antigen test -confirmed SARS -CoV -2 infection through Day  14 for each treatment group. The 
compound sy mmetry variance -covariance structure will be used to account for the correlation 
among the participants associated with the same index case. The risk ratio between 5 -day 
regimen of PF -07321332/ritonavir versus placebo group and 10 -day regimen of 
PF-07321332/ritonavir versus placebo group and the corresponding 95% CIs will be 
calculated based on the GEE model using a log link function. Comparisons between the 
5-day and 10 -day regimens of PF -07321332/ritonavir versus placebo will be presented as a 
risk reduction wi th 95% CI s, which is calculated as [ADDRESS_1069093] -confirmed infection. For COVID - 19 
related hospi[INVESTIGATOR_778377] -19-related death, it will be considered as achieving the 
event. 
Multiplicity  adjustment for primary  endpoint will be made for multiple comparisons using 
Hochberg method. 65
Significance level will be determined using the O’Brien -
Fleming approach at the interim 
analysis and the final analy sis. The overall ty pe I error rate is maintained at 5% (2 -sided).
Sensitivity  analy ses will be performed to the primary  efficacy  endpoint using PP anal ysis set.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 789.3.3. Key Secondary Efficacy Endpoint(s)/Estimand(s) Analysis
The key  secondary  efficacy  endpoint is:
the proportion of participants with sy mptomatic RT -PCR or rapi d antigen 
test-confirmed SARS -CoV -[ADDRESS_1069094] 
a negative RT -PCR result at baseline and who are at increased risk of severe 
COVID -19 illness.
The anal yses will be performed similarly  to the primary  efficacy  anal ysis using mITT2 
population.
9.3.4. Secondary Endpoint(s)/Estimand(s) Analysis
Incidence of TEAEs.
Incidence of SAEs and AEs leading to discontinuation.
Proportion of participants with COVI D-[ADDRESS_1069095] a negative RT -PCR result at baseline 
and who are at increased risk of severe COVID -19 illness.
Proportion of participants with asy mptomatic RT -PCR or rapid antigen 
test-confirmed SARS -CoV -[ADDRESS_1069096] a 
negative RT -PCR result at baseline.
Time to RT -PCR or rapid antigen test -confirmed SARS -CoV -[ADDRESS_1069097] a negative RT -PCR result at baseline.
Proportion of participants with symptomatic RT -PCR or rapid anti gen test -confirmed 
SARS -CoV -[ADDRESS_1069098] a positive RT- PCR 
result at baseline.
Proportion of participants with symptomatic RT -PCR or rapid antigen test -confirmed 
SARS -CoV -[ADDRESS_1069099] either a negative or 
positive RT -PCR result at baseline.
Proportion of participants with no, mild, moderate, or severe signs and s ymptoms 
attributed to COVID -[ADDRESS_1069100] a negative 
RT-PCR result at baseline.
Number of days of sy mptomatic SARS -CoV -[ADDRESS_1069101] a negative RT -PCR result at baseline.
PF-07321332 PK in plasma and whole blood (if feasible).
Proportion of participants with death (all- cause) through Day  [ADDRESS_1069102] a negative RT -PCR result at baseline.
Viral titers measured via RT -PCR in nasal swabs over time for participants who have 
a negative RT -PCR result at baseline.

PF-07321332
Protocol C4671006Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 79•Viral titers measured via RT-PCR in nasal swabs over time for participants who have 
a positive RT-PCR result at baseline.
•Number of days of hospi[INVESTIGATOR_295370]-19-related 
hospi[INVESTIGATOR_270522] [ADDRESS_1069103] a negative RT-PCR at baseline.
•Number of COVID-[ADDRESS_1069104] a negative RT-PCR at baseline.
Details on the definitions and analyses of secondary endpoints will be described in the SAP.
9.3.6. Other Safety Analyses
Safety analyses will be carried out for the Safety population.  
The safety assessments include AEs, laboratory assessments, physical examinations, and 
vital signs. No formal statistical analysis will be conducted on any of the other safety data listed above.
[IP_ADDRESS]. Laboratory
Clinical laboratory data will be subjected to clinical review, summarized by [CONTACT_295425].
[IP_ADDRESS]. Physical Examination and Vital Signs
Physical examination and vitals will be descriptively summarized by [CONTACT_1570].
9.3.7. Other Analyses 
Pharmacogenomic or biomarker data from Retained Research Samples ( Section 8.5.2 and 
Section 8.6.5 ) may be collected during or after the trial and retained for future analyses; the 
results of such analyses are not planned to be included in the CSR. 
PRO data (WPAI, EQ-5D-5L, and Global Impression Questions) will be collected during the 
trial and are not planned to be included in the CSR.
[IP_ADDRESS]. PK Analyses
Descriptive statistics and graphical summaries of PF-07321332 concentrations will be 
generated. PK samples will be collected as described in the SoA. Additional PK sampling 
may be self collected in a subset of participants using Tasso, if feasible. Ritonavir concentrations may also be reported. PK data from this study may be combined with other studies and analyzed using population PK approaches. Results from any population PK analyses will be reported outside of the clinical study report.CCI
PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 809.4.Interim Analyses
An interim anal ysis will be conducted for efficacy, futility , and sample size re -estimation and 
reviewed b y an independent E-DMC after a prespecified accrual of participants (ie, before or 
at approximately  70% overall participants have completed the Day  14 assessments with a 
minimum number of 24 participants having s ymptomatic infection [mI TT anal ysis set] ). The 
nominal significance level for the interim and final anal yses is determined by  [CONTACT_778423]-DeMets procedure with an O’Br ien-Fleming stoppi[INVESTIGATOR_3106] , with an overall 
two-sided ty pe I error rate of 5%. O’Brien -Fleming approach provides relatively  conservative 
stoppi[INVESTIGATOR_778378], ie, the nominal level for interim analy sis for efficacy  
and futility  is 0.[ADDRESS_1069105] number of participants included in the 
interim analy sis.
At the predefined interim anal ysis, the sample size may  be adjusted ba sed on sample size 
re-
estimation with maximum increase of 30%. A well -established method such as CHW66
will be used to control the Ty pe I error probability. Besides stoppi[INVESTIGATOR_007] a 
PF-07321332/ritonavir arm for safet y or futility , a PF -07321332/ritonavir arm ( 5-day or 
10-day regimen) may  be discontinued based on overall evaluation of efficacy  and safet y 
profiles between the 2 arms.
Before an y interim anal ysis is performed, the details of the objectives, decision criteria, 
dissemination plan, and method of maint aining the study  blind as per [COMPANY_007]’s SOPs will be 
documented and approved in a DMC charter. In addition, the analy sis details will be 
documented and approved in the SAP.
9.5.Sample Size Determination
Based on the results from Study  C4671005, which showed 
PF-07321332/ritonavir treatment 
significantl y reduced the risk of hospi[INVESTIGATOR_295340] y cause b y 89% compared 
with placebo in nonhospi[INVESTIGATOR_778364] -19 who were at 
increased risk of progression to severe disea se when they  were treated within 3 day s of 
symptom onset, and the high relative risk reduction (approximately  80%) observed in 
Regeneron REGEN -COV post -exposure proph ylaxisstudy , the risk reduction between 
PF-07321332/ritonavir group versus placebo group is assumed to be 70%. The symptomatic 
infection rate assumption in the placebo group is adjusted to 4% based on theobserved 
seropositivity  rate in this study and the impact of seropositivity  on the incidence of primary  
endpoint events in the REGEN -COV pos t-exposure proph ylaxis study  where the incidence of 
symptomatic infection was 2% in participants who were seropositive and 8% in those who 
were seronegative .2As of January  2022, a large percentage of participants were observed to 
be seropositive . Based on a 2% placebo event rate for participants who were seropositive and 
8% placebo rate for participants who were seronegative observed in the REGEN -COV 
postexposure prophy laxis study ,2the expected placebo rate across the 2 groups is estimated 
to be approximately  3%. In addition, based upon emerging epi[INVESTIGATOR_778379] ,34which suggests higher infectivity  than with prior variants, the placebo rate 
is adjusted to be 4%.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 81Among baseline RT -PCR negative participants, assuming a 4% s ymptomatic infection rate in 
the placebo group, a 70% reduction in sy mptomatic infection ( 1.2% s ymptomatic infection 
rate) in the PF -07321332/ritonavir group (5 -day and 10 -day regimen), a sample size of 
821participants per group ( 2463 participants total) will provide approximately  90% power 
for each comparison between 5 -day and 10
-day regimens of PF -07321332/ritonavir group 
versus placebo group under a 2 -sided t ype-1 error rate of 5%. Assuming approximately  5% 
of participants with negative rapid antigen test result at screening will have a positive 
RT-PCR result at baseline, and assuming an approxim ately  10% dropout rate, the total 
sample size for this study will be approximately  [ADDRESS_1069106] 
34 participants had s ymptomatic infection for the primary  anal ysis. However, enrollment 
may continue until the 70% interim anal ysis has been completed.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 8210. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical C onsiderations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines, including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines;
Applica ble ICH GCP guidelines;
Applicable laws and regulations, including applicable privacy  laws.
The protocol, protocol amendments, I CD, SRSD(s), and other relevant documents (eg, 
advertisements) must be reviewed and approved by [CONTACT_456], submitted to an I RB/EC by  
[CONTACT_093], and reviewed and approved b y the I RB/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y substantial amendments to the protocol will require health authority  
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study  participants.
The investi gator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC;
Notify ing the IRB/EC of S AEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies (if applicable), European Medical Device Regulation 
2017/745 for clinical device research (if applicable), and all other applicable local 
regulations.
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibit ion or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study 
intervention, P fizer should be informed immediately . 

PF-[ADDRESS_1069107] ete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. I nvestigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process 
The investigator or his/her representative will explain the nature of the study, including the 
risks and benefits, to the participant or his/her legally  authorized representative and answer 
all questions regarding the study . The participant or his/her legall y authorized representative 
should be given sufficient time and opportunity  to ask questions and to decide whether or not 
to participate in the trial.
Participants must be informed that their participation is volunta ry. Participants or their 
legally  authorized representative will be required to sign a statement of informed consent that 
meets the requirements of 21 CFR 50, local regulations, I CH guidelines, privacy  and data 
protection requirements, where applicable, an d the I RB/EC or study  center.
The investigator must ensure that each study  participant or his or her legally  authorized 
representative is fully  informed about the nature and objectives of the study , the sharing of 
data related to the study
, and possible ri sks associated with participation, including the risks 
associated with the processing of the participant’s personal data. 
The participant or his or her legall y authorized representative must be informed that his/her 
personal stud y-related data will be use d by [CONTACT_78271]. The level of disclosure must also be explained to the participant or his or her 
legally  authorized representative.
The participant or his or her legall y authorized representative must be informed that his/her 
medical records may  be examined by  [CONTACT_78272] b y the sponsor, b y appropriate I RB/EC members, and by  [CONTACT_78273].
The investigator further must ensur e that each study  participant or his or her legall y 
authorized representative is fully  informed about his or her right to access and correct his or 
her personal data and to withdraw consent for the processing of his or her personal data.

PF-[ADDRESS_1069108] 
current version of the ICD(s) during their participation in the study .
A cop y of the ICD(s) must be provided to the participant or the participant’s legall y 
authorized representative.
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at t he study  site in encry pted electronic form and 
will be password- protected to ensure that only authorized study  staff have access. The study  
site will implement appropriate technical and organizational measures to ensure that the 
personal data can be recove red in the event of disaster. In the event of a potential personal 
data breach, the study site will be responsible for determining whether a personal data breach 
has in fact occurred and, if so, providing breach notifications as required by [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any  
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant -specific code. The study  site will 
maintain a confidential list of participants who participate d in the study , linking each 
participant’s numerical code to his or her actual identity  and medical record ID. In case of 
data transfer, the sponsor will protect the confidentiality of participants’ personal data 
consistent with the clinical study  agreement and applicable privacy  laws.
10.1.5. Committees Structure
[IP_ADDRESS]. Data Monitoring Committee 
This study  will use an E -DMC. The E- DMC is independent of the stud y team and includes 
only external members. The E-DMC charter describes the role of the E- DMC in more detail.
The E-DMC will be responsible for ongoing monitoring of the efficacy  and safet y of 
participants in the study  according to the charter. The recommendations made by  [CONTACT_941] E- DMC
will be forwarded to the appropriate authorized [COMPANY_007] personnel for review and fin al 
decision. [COMPANY_007] will communicate such decisions, which may  include summaries of 
aggregate anal yses of safety  data to regulatory  authorities, investigators, as appropriate. 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 85In addition to up to weekly  reviews of safet y data, the E -DMC will review the f ollowing:
Sentinel cohort safet y review : The E -DMC will review unblinded safet y data after 
approximately  the first [ADDRESS_1069109] completed Day 10 of the study , at which 
point enrollment will be paused pending E -DMC review of the safety data. After 
review of the sentinel cohort, the frequency  of safety  reviews may  be reduced 
subsequently  based on E -DMC recommendations.
Interim anal ysis: An interim analy sis will be conducted for efficacy , futility , and 
sample size re- estimation and reviewed by [CONTACT_941] E -DMC after a prespecified accrual of 
participants (ie, before or at approximately  70% overall participants have completed 
the Day  14 assessments with a minimum number of 24 participants having 
symptomatic infection events [mITT anal ysis set] ). 
The E
-DMC wil l review all deaths that occur during the stud y. A pause in enrollment 
pending E -DMC review will occur if 2 participants experience a Grade 4 or higher AE that is 
deemed related to study intervention as determined by [CONTACT_295428].
10.1.6. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, [COMPANY_007] reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accu rate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007] -sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These results are 
submitted for posting in accordance with the format and timelin es set forth by  [CONTACT_20008].
EudraCT
[COMPANY_007] posts clinical trial results on EudraCT for [COMPANY_007] -sponsored interventional studies in 
accordance with the format and timelines set forth by  [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which any  data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 86[COMPANY_007] -sponsored interventional studies at the same time the corresponding study  results are 
posted to www.clinicaltrials.gov.
Docum ents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this policy , includes clinical 
overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol 
amendments, sample CRFs, and statistical methods. Clinical data, under Phase 2 of this 
policy , includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via the centralized procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 01 July  2015.
Data sharing
[COMPANY_007] provides researchers secu re access to patient -level data or full CSRs for the purposes 
of “bona -fide scientific research” that contributes to the scientific understanding of the 
disease, target, or compound class. [COMPANY_007] will make data from these trials available 
24months after study  completion. Patient- level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personally  identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate com petencies to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data ent ries are accurate and correct by  [CONTACT_20010].
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document.
The investigator must ensure that the CRFs are securel y stored at the study site in encry pted 
electronic form and are password protected to prevent access b y unauthorized third parties.
QTL s are predefined parameters that are monitored during the study . Important deviations 
from the QTLs and an y remedial actions taken will be summarized i n the clinical study  
report.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 87verification may  also occur after study  completion. I t is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy , including definition o f study  critical data items and 
processes (eg, risk- based initiatives in operations and quality  such as risk management and 
mitigation strategies and anal ytical risk -based monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual, or on -site monitoring), are provided in the data management plan and 
monitoring plan maintained and utilized by  [CONTACT_36613].
The sponsor or designee is responsible for the data mana gement of this study , including 
quality  checking of the data.
Records and documents, including signed ICDs, pertaining to the conduct of this study  must 
be retained b y the investigator for [ADDRESS_1069110] ensure that the records continue to be stored securel y for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from al l systems.
The investigator(s) will notify the sponsor or its agents immediately  of any  regulatory  retain  
notification in relation to the study . Furthermore, the investigator will cooperate with the 
sponsor or its agents to prepare the investigator site f or the inspection and will allow the 
sponsor or its agent, whenever feasible, to be present during the inspection. The investigator 
site and investigator will promptly  resolve an y discrepancies that are identified between the 
study  data and the participant 's medical records. The investigator will promptly  provide 
copi[INVESTIGATOR_19946]. Before response submission to 
the regulatory  authorities, the investigator will provide the sponsor or its agents with an 
opportunity  to review and comment on responses to any  such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
Definition of what constitutes source data and its origin can be found in the monitoring plan, 
which is maintained by  [CONTACT_456].

PF-[ADDRESS_1069111] maintain accurate documentation (source data) that supports the 
information entered in the CRF.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently approved protocol and any other stud y 
agreements, I CH GCP guidelines, and all applicable regulatory  requirements.
10.1.9. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site clo sure at any  time upon notification to the sponsor 
or designee/CRO if requested to do so by  [CONTACT_51025] I RB/EC or if such termination is 
required to protect the health of study  participants.
Reasons for the earl y closure of a stud y site b y the sponsor m ay include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or the ICH GCP 
guidelines;
Inadequate recruitment of participants by  [CONTACT_093]; 
Discontinuation of further study  intervention development.
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO(s) used in the study  of 
thereason for termination or suspension, as specified by  [CONTACT_20013]. The investigator shall promptly  inform the participant and should assure 
appropriate participant therap y and/or follow -up.

PF-[ADDRESS_1069112] will control as to termination rights.
10.1.10. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1 y ear after the end of the study  
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications, 
such as secondary  manuscripts, and submits all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments, and the investigator will, on request, remove an y previously undisclosed 
confidential information before disclosure, except for any  study -or [COMPANY_007] 
intervention -related information necessary  for the appropriate scientific presentation or 
understanding of the study  results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  [CONTACT_19483].
The sponsor will comply  with the requirements for publication of the overall study  results 
covering all investigator sites. I n accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data. I n this case, a coordinati ng investigator will be designated b y mutual 
agreement.
Authorship of publications for the overall study  results will be determined by  [CONTACT_78275] I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publica tion is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.11. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately qualified medical personnel for the 
study  is doc umented in the study  contact [CONTACT_20015]/study  portal or other electronic s ystem. 
To facilitate access to appropriatel y qualified medical personnel for study -related medical 
questions or problems, participants are pr ovided with an Emergency  Contact [CONTACT_74057] (ECC) at 
the time of informed consent. The ECC contains, at a minimum, (a) protocol and study  
intervention identifiers, (b) participant’s stud y identification number, (c) site emergency 
phone number active 24 hours/day , 7 day s per week, and (d) [COMPANY_007] Call Center number.
The ECC is intended to augment, not replace, the established communication pathway s 
between the investigator, site staff, and study  team. The ECC is to be used by  [CONTACT_778424]-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 90professionals not involved i n the research stud y only , as a means of reaching the investigator 
or site staff related to the care of a participant. The [COMPANY_007] Call Center number should only  be 
used when the investigator and site staff cannot be reached. The [COMPANY_007] Call Center number i s 
not intended for use b y the participant directly ; if a participant calls that number directl y, he 
or she will be directed back to the investigator site.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 9110.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory  results may  be reported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer used by  [CONTACT_20019] , or as derived 
from calculated values. These additional tests would not require additional collection of 
blood. Unscheduled clinical laboratory  measurements may  be obtained at any  time during the 
study  to assess an y percei ved safet y issues.
Table 1. Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry Other Additional Tests (Needed 
for Hy’s Law)
Hem oglobin
Hem atocrit
RBC count
Platelet count
WBC count
Total neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)BUN or urea
Creatinine a
Glucose
Calcium
Sodium
Potassium
Chloride
Total CO 2
(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphatase
Albumin
Total proteinFerritin
hsCRP
Procalcitonin
LDH
CK
Haptoglobin
Thyroid function
TSH
T4 (free)
Coagulation 
PT/aPTT
Fibrinogen
D-dimer
SARS -CoV- 2 
serology 
IgM, IgG
Other
FSHb
Pregnancy test 
(β-hCG)cAST, ALT (repeat)
Total bilirubin (repeat)
Albumin 
Alkaline phosphatase 
(repeat)
Direct bilirubin
Indirect bilirubin
Creatine kinase
GGT
PT/INR
Total bile acids
Acetaminophen drug and/or 
protein adduct levels
a.eGFR will be calculated using the method developed by [CONTACT_91019] -EPI [INVESTIGATOR_295373].[ADDRESS_1069113] for the protocol unless serum testing is required by [CONTACT_216483]/EC. Serum or urine -hCG for female participants of childbearing potential.
The investigator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study  in the AE section of the CRF.  

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 9210.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluatin g, Follow -Up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporall y associated with the use of study intervention, whether or not 
considered related to the study  intervention.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally
 associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator. An y abnormal laboratory test 
results that meet an y of the conditions below must be recorded as an AE:
Is associated with accompany ing s ymptoms.
Requires additional diagnostic testing or medical/surgical intervention.
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including either an 
increase in frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration, even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug- drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an int entional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 93Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/di sorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of an SAE
An SAE is defined as any u ntoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life -threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event that 
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_778380] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur durin g hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the 
AE should be considered serious.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 94Hospi[INVESTIGATOR_5186] n for elective treatment of a preexisting condition that did not worsen 
from baseline is not considered an AE.
d.Results in persistent or significant disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), that may  interfere wi th or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a [COMPANY_007] product of an infectious agent, pathogenic 
or non- pathogenic, is considered serious.  
g.Theevent may  be suspected from clinical s ymptoms or laboratory  findings indicating 
an infection in a participant exposed to a [COMPANY_007] product. The terms “suspected 
transmission” and “transmission” are considered sy nony mous. These cases are 
considered unexpect ed and handled as serious expedited cases b y pharmacovigilance 
personnel. Such cases are also considered for reporting as product defects, if 
appropriate.
h.Other situations:
Medical or scientific judgment should be exercised by [CONTACT_778425], such as significant 
medical events that may jeopardize the participant or may  require medical or 
surgical intervention to prevent one of the other outcomes listed in the above 
definition. These eve nts should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], o r development of drug 
dependency  or drug abuse.
10.3.3. Recording/Reporting and Follow -Up of AEs and/or SAEs During the Active 
Collection Period 
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the CT SAE Report Form to [COMPANY_007] Safet y throughout the active 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 95collection period. These requirements are delineated for 3 ty pes of events: (1) SAEs; (2) 
nonse rious AEs; and (3) exposure to the study  intervention under stud y during pregnancy  
or breastfeeding, and occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF. When the same data are collected, the forms must be 
completed in a consistent manner. AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours 
of Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeeding, All AEs or SAEs 
associated with exposure 
during pregnancy  or 
breastfeeding
Note:   Instances of EDP or 
EDB not associated with an 
AE or SAE are not 
captured in the CRF.All instances of EDP are 
reported (whether or not 
there is an associated 
SAE) *
All instances of EDB are
reported (whether or not 
there is an associated 
SAE). **
Environmental or 
occupational exposure to 
the product under stud y to 
a non -participant (not 
involving EDP or EDB).None.  Exposure to a study  
non-participant is not 
collected on the CRF.The exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported. ***
*EDP (with or without an associated AE or SAE): any pregnancy information is reported to 
[COMPANY_007] Safety using CT SAE Report Form and EDP Supplemental Form; if the EDP is 
associated with an SAE, then the SAE is reported to [COMPANY_007] Safety using the CT SAE Report 
Form . 
** EDB is reported to [COMPANY_007] Safety using the CT SAE Report Form which w ould also include 
details of any SAE that mig ht be associated w ith the EDB. 
***Environmental or Occupational exposure: AEs or SAEs associated with occupational exposure 
are reported to [COMPANY_007] Safety using the CT SAE Report Form. 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 96When an AE or SAE occurs, it is the responsibility  of the investig ator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety  in lieu of completion of the CT SAE Report 
Form/AE or SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety. In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953] .
The investigator will attempt to establish a diag nosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories, which are based on the 
Division of AIDS (DAIDS) Table for Grading the Severity  of Adult and Pediatric Adverse 
Events,64version 2.1 (July 2017):
GRADE Clinical Description of Severity
1 MILD adverse event
2 MODERATE adverse event
3 SEVERE adverse event
4 POTENTIALLY LIFE -THREATENING event 
5 DEATH RELATED TO adverse event
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.
A “reasonable possibility” of a r elationship convey s that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 97Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well a s the temporal relationship of the event to study intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products, in his/her assessment.
For each AE or SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE or SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event be fore the initial transmission of the SAE data to the sponsor.
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention” for reporting 
purposes, as defined by  [CONTACT_456]. In addition, if the investigator determines that 
an SAE is associated with study  procedures, the investigator must record this 
causal relationship in the source documents and CRF, and report such an 
assessment in the dedicated section of the CT SAE Report Form and in accordance 
with the SAE reporting requirements.
Follow -Up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations, as medically  indicated or as requested by  [CONTACT_103], to elucidate the nature and/or causalit y of the AE or SAE as full y as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare providers.
If a participant dies during participation in the study  or during a recognized 
follow -up period, the investigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings, including histopathology .

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 98New or updated information will be recorded in the originally  submitted 
documents.
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety  will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) to report the event within 24 hours.
The site will ent er the SAE data into the electronic sy stem as soon as the data 
become available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a sit e receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next secti on) or to [COMPANY_007] Safety  by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working, notification by  [CONTACT_20021] a cop y of the CT SAE Report Form sent by  [CONTACT_20022].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report F orm pages within the designated reporting 
time frames.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 9910.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the int ervention period and for at least [ADDRESS_1069114] dose of stud y intervention, which
corresponds to the time needed to eliminate reproductive safet y risk of the study  
intervention(s) :
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifesty le (abstinent on a long -term and persistent basis) and 
agree to remain abstinent. 
OR
Must agree to use contraception/barrier as detailed below:
Agree to use a male condom when having sexual intercourse with a woman of 
childbearing potential who is not currently  pregnant.
In addition to male condom use, a highl y effective method of contraception may be 
considered in WOCBP partners of male participants (refe r to the list of highly  
effective methods below in Section 10.4.4).
10.4.2. Female Participant Reproductive Inclusion Criteri a
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 1 of the following conditions applies:
Is not a WOCBP (see definitions below in 
Section 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is highly  effective (with a 
failure rate of <1% per year), as described below, during the intervention period 
and for at least [ADDRESS_1069115] dose of stud y intervention, which 
corresponds to the time needed to eliminate an y reproductive safety  risk of the 
study  intervention(s). If a highl y effective method that is user depend ent is 
chosen, a second effective method of contraception, as described below, must also
be used. The investigator should evaluate the effectiveness of the contraceptive 
method in relationship to the first dose of stud y intervention.

PF-[ADDRESS_1069116] 
also be used if the participant is using estradiol -containing contraceptives.
The investigator is re sponsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and u
ntil becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following: 
Documented h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than the 
above, (eg, mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history  
interview. The method of documentation should be recorded in the participant’s medical 
record for the stud y.
2.Postmenopausal female:
A postmenopausal sta te is defined as no menses for 12 months without an 
alternative medical cause.  I n addition:
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 50 years of age and not using hormonal 
contraception or HRT. 
A female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highly effective contraception methods 

PF-[ADDRESS_1069117] 
discontinue HRT to allow confirmation of postmenopausal status before study  
enrollment.
10.4.4. Contraception Methods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical t rials.
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device.
3.Intrauterine hormone -releasing s ystem.
4. Bilateral tubal occlusion (eg, bilateral tubal ligation).
5.Vasectomized partner:
A vasectomized partner is a highl y effective contraceptive method provided that 
the partner is the sole sexual partner of the woman of childbearing potential and 
the absence of sperm has been confirmed. If not, an additional highl y effective 
method of contraception shoul d be used. The spermatogenesis cy cle is 
approximately  90 day s.
6.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation:
Oral;
Intravaginal;
Transdermal.
7.Progestogen -only hormone contraception associate d with inhibition of ovulation:
Oral;
Injectable.
8.Sexual abstinence:
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  interventi on. The reliability of sexual abstinence needs to be 

PF-[ADDRESS_1069118] also be used when 
option 6 or 7 are chosen above:
Male or female condom with or without spermicide;
Cervical cap, diaphragm, or sponge with spermicide;
A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).
Because ritonavir may  reduce the effect of estradiol- containing contraceptives when agents 
are coadministered, a barrier method or other non -
hormonal method of contraception must 
also be used if the participant is using estradiol -containing contraceptives.

PF-07321332
Protocol C4671006Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 103CCI
CCI
PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE].6. Appendix 6: Liver Safety: Suggested Actions and Follow -Up Assessments and 
Study Intervention Rechallenge Guidelines
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury  but adapt 
are termed “adaptors.” In som e participants, transaminase elevations are a harbinger of a 
more serious potential outcome. These participants fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI. 
Participants who experience a transaminase elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are “adaptors” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations (>2 ×
ULN) b y several days or weeks. The increase in TBili ty pi[INVESTIGATOR_1306] y occurs while AST/ALT is/are 
still elevated above 3 ×ULN (ie, AST/ALT and TBili values will be elevated within the same 
laboratory  sample). In rare instances, by  [CONTACT_22858], AST/ALT 
values might have decreased. This occurrence is still regarded as a potential DILI. Therefore, 
abnormal elevations in either AST OR ALT in addition to TBili that meet the criteria 
outlined below are considered potential DILI (assessed per Hy ’s law criteria) cases and 
should alway s be considered important medical events, even before all other possible causes 
of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and u nderly ing conditions. Participants who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participants with AST/ALT an d TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participants with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values a bove the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).

PF-[ADDRESS_1069119]/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law ca se should be reviewed with the sponsor.
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_1069120] and AL T and TBili for suspected Hy’s law 
cases, additional laboratory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alka line phosphatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analy ses at the time of the recognized initial 
abnormalities to determine etiology . A detailed history , including relevant information, such 
as review of ethanol, acetaminophen/paracetamol (either by  [CONTACT_20025] a coformulated 
product in prescription or over -the-counter medications) , recreational drug, or supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collecte d. Further testing for acute 
hepatitis A, B, C, D, and E infection, liver imaging (eg, biliary  tract), and collection of serum 
samples for acetaminophen /paracetamol drug and/or protein adduct levels may  be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have be en received and have excluded an alternative etiology .

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE].7. Appendix 7: ECG Findings of Potential Clinical Concern (No Longer Applicable)

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE].8. Appendix 8: Prohibited Concomitant Medications That May Result in DDI  
PF-07321332 and ritonavir are both primarily  metabolized by  [CONTACT_097]3A4. Therefore, 
concomitant use of an y medications or substances that are strong inducers of CYP3A4 are 
prohibited within 28 days prior to dosing of stud y intervention and during study  treatment.
Additionally , ritonavir and PF -07321332 are inhibitors of CYP3A4. Therefore, medications 
highl y dependent on CYP3A4 for clearance and for which elevated plasma concentrations 
may be associated with serious and/or life- threatening events are not permitted during dosing 
of PF -07321332/ritonavir (at le ast [ADDRESS_1069121] dose of study  intervention –see below) and for [ADDRESS_1069122] dose of PF- 07321332/ritonavir. Ritonavir also appears to induce CYP3A, CYP1A2, 
CYP2C9, CYP2C19, and CYP2B6 as well as other enzymes, including glucuronos yl 
transferase. Since ritonavir [ADDRESS_1069123] of drugs prohibited for potential DDI concerns with the IMP may  be revised during 
the course of the study  with written notification from sponsor, to include or exclude specific 
drugs or drug categories for various reasons (eg, emerging DDI results for the IMP, 
availability  of new information in literature on the DDI potential of other drugs).  
This is not an all -inclusive list. Site staff should consult with the sponsor or designee with 
any questions regarding potential DDI.

PF-[ADDRESS_1069124] not use these medications within 28 days 
prior to randomization and during dosing of PF -07321332/placebo and ritonavir/pl acebo.
Drug Class Specific Medication Clinical Comments
Anti-cancer drugs Apalutamide Reduced concentrations of 
PF-07321332/ritonavir; may result in 
suboptimal concentrations.Anticonvulsants Phenytoin, Carbamazepi[INVESTIGATOR_050], 
Phenobarbital 
Antimycobacterials Rifampin
Herbal Products St. John’s Wort
Prohibited Medications Dependent on CYP450 3A4 for Clearance or with other Notable 
Interactionsa
These medications are prohibited for at least [ADDRESS_1069125] dose of PF -0321332/placebo and 
ritonavir/placebo, through [ADDRESS_1069126] dose of PF -07321332/placeb o and ritonavir/placebo. If a 
participant cannot temporarily interrupt the prohibited medication during this period, they should be 
considered ineligible.
Drug Class Specific Medication Clinical Comments
Alpha 1 -Adrenoreceptor 
AntagonistAlfuzosin Risk of hypotension, syncope
Analgesics Pi[INVESTIGATOR_18234], Propoxyphene, 
Pethidine Analgesic concentrations may increase.
Antianginal Ranolazine Risk of cardiac arrhythmias 
Antiarrhythmics Dronedarone , Amiodarone, 
Flecainide, Propafenone, QuinidineRisk of cardiac arrhythmias
Anti-gout Colchicine Ritonavir 100 mg twice daily increased 
colchicine AUC 296% and C max184%. 
Potential for serious and/or 
life-threatening reactions in patients 
with renal and/or hepatic impairment.
Antipsychotics Clozapi[INVESTIGATOR_050], Lurasid one, Pi[INVESTIGATOR_295376].
Ergot Derivatives Dihydroergotamine, Ergotamine, 
MethylergonovineRisk of acute ergot toxicity (peripheral 
vasospasm and ischemia of the 
extremities)
Lipid low ering drugs 
(HMG CoA Reductase 
Inhibitors)Lovastatin, Simvastatin Risk of rhabdomyolysis
PDE -5 Inhibitors for 
pulmonary arterial 
hypertension treatmentSildenafil (Revatio) when used for 
pulmonary arterial hypertensionRisk of visual disturbances, 
Co-administration may result in visual 
abnormalities, hypotension, prolonged 
erection, and syncope.
Sedatives/
Hypnoticsoral Midazolam, Triazolam Risk of prolonged sedation, respi[INVESTIGATOR_41826], or hypnotic concentrations   
a.Note: If a drug is not listed, it should not automatically be assumed it is safe to co -administer

PF-[ADDRESS_1069127] dose of PF -07321332/placebo and ritonavir/placebo, through 
4days after the last dose of PF -07321332/placebo and ritonavir/placebo. If a participant cannot temporarily 
interrupt the prohibited medication during this period, they should be considered ineligible.   
Drug Class Specific Medication Clinical Comments 
Alpha [ADDRESS_1069128] Tamsulosin, Silodosin, Doxazosin 
(>2mg daily), Terazosin (>5 mg 
daily), Risk of hypotension, syncope 
Analgesics
Opi[INVESTIGATOR_778381], Oxycodone
Buprenorphine 
Lofexidine Moderate to w eak decreases in 
methadone concentrations have been 
observed. 
Analgesic concentrations may increase.
Co-administration may increase 
concentrations of Buprenorphine and 
Lofexidine.
Anticancer drugs Abemaciclib, 
Ceritinib,
Dasatinib, 
Encorafenib,
Ibrutinib, 
Ivosidenib, 
Neratinib, 
Nilotinib, 
Venetoclax,
Vinblastine, 
VincristineCo-administration contraindicated due to 
potential loss of virologic response and 
possible resistance.
Avoid co -administration of Encorafenib 
or Ivosidenib due to potential risk of 
serious adverse events such as QT 
interval prolongation. Avoid use of 
Neratinib, Venetoclax or Ibrutinib.
Co-administration of Vincristine and 
Vinblastine may lead to significant 
hematologic or gastrointestinal side 
effects.
For further information, refer to 
individual product label for anticancer 
drug.
Anticoagulants/ 
antiplateletRivaroxaban, 
Warfarin Possible increased risk of bleeding 
Possible decreased w arfarin effects. 
Closely monitor INR if co -administration 
with Warfarin is necessary.

PF-[ADDRESS_1069129] dose of PF -07321332/placebo and ritonavir/placebo, through 
4days after the last dose of PF -07321332/placebo and ritonavir/placebo. If a participant cannot temporarily 
interrupt the prohibited medication during this period, they should be considered ineligible.   
Drug Class Specific Medication Clinical Comments 
Antidepressant Bupropi[INVESTIGATOR_778382]. 
Adverse reactions of nausea, dizziness, 
hypotension, and syncope have been 
observed follow ing co -administration of 
Trazodone and Ritonavir. A lower dose 
of Trazodone should be considered. 
Refer to Trazadone product label for 
further information.
Anti-infective 
(antibacterials)Erythromycin Co-administration may increase 
erythromycin concentrations.
Clarithromycin Co-administration may increase 
clarithromycin concentrations.
Antimycobacterials Bedaquiline Co-administration contraindicated due to 
potential loss of virologic response and 
possible resistance. Alternate 
antimycobacterial drugs such as 
Rifabutin should be considered.
(antifungals) Isavuconazole
Itraconazole 
Posaconazole 
Ketoconazole 
VoriconazoleRefer to Ketoconazole, 
Isavuconazonium Sulfate, and 
Itraconazole product labels for further 
information.
Co-administration of Ritonavir w ith 
Voriconazole may result in reduction in 
Voriconazole levels. 
Antihistamines Astemizole, Terfenadine Risk of cardiac arrhythmias 
Antipsychotics Quetiapi[INVESTIGATOR_295380], Perphenazine, 
Aripi[INVESTIGATOR_4253], Brexpi[INVESTIGATOR_4253], 
Cariprazine, Iloperidone, 
Thioridazine, Ziprasidone Co-administration may increase 
Quetiapi[INVESTIGATOR_778383] -related toxicity.  
Potential for increased levels of 
antipsychotics. 
Cardiac Medications 
(beta blockers) Carvedilol, Metoprolol, Timolol Co-administration may increase 
concentration of Carvedilol, Metoprolol, 
Timolol. 

PF-[ADDRESS_1069130] dose of PF -07321332/placebo and ritonavir/placebo, through 
4days after the last dose of PF -07321332/placebo and ritonavir/placebo. If a participant cannot temporarily 
interrupt the prohibited medication during this period, they should be considered ineligible.   
Drug Class Specific Medication Clinical Comments 
Calcium channel blockers  Diltiazem, Verapamil, Nifedipi[INVESTIGATOR_050], 
amlodipi[INVESTIGATOR_050] (> 5 mg daily), 
felodipi[INVESTIGATOR_050], ni cardipi[INVESTIGATOR_778384]-administration may increase 
concentrations of calcium channel 
blockers. The impact on the PR interval 
of co -administration of ritonavir with 
other drugs that prolong the PR interval 
(including calcium channel blockers) has 
not been evaluated.   A dose decrease 
may be needed for these drugs when 
co-administered with PAXLOVID.
Cardiac glycosides Digoxin Caution should be exercised when 
co-administering PAXLOVID w ith 
digoxin, with appropriate monitoring of 
serum digoxin levels. 
Refer to the digoxin product label for 
further information .
Eplerenone Co-administration increases eplerenone 
concentrations. 
Ivabradine Co-administration increases ivabradine 
concentrations. 
Corticosteroids 
(inhaled or intranasal) 
(systemic) 
(Local injections, 
including intra- articular, 
epi[INVESTIGATOR_13873], or intra -orbital)Budesonide, 
Ciclesonide, 
Mom etasone
Betam ethasone 
Budesonide 
Betam ethasone, 
Methylprednisolone, Triamcinolone Co-administration can increase 
concentration of Budesonide, 
Ciclesonide, and Mometasone and can 
result in adrenal insufficiency and 
Cushing’s syndrome. 
Co-administration can increase 
concentration of Betamethasone, and 
Budesonide and can result in adrena l 
insufficiency and Cushing’s syndrome. 
Co-administration can increase 
Betam ethasone, Methylprednisolone, 
and Triamcinolone concentrations and 
can result in adrenal insufficiency and 
Cushing’s syndrome
Endothelin receptor 
antagonists Bosentan Bosentan should be discontinued at least 
[ADDRESS_1069131] acting 
antivirals (DAAs) Elbasvir/Grazoprevir,
Glecaprevir/Pi[INVESTIGATOR_778385].
It is not recommended to co -administer 
ritonavir with Glecaprevir/Pi[INVESTIGATOR_187761]. 

PF-[ADDRESS_1069132] dose of PF -07321332/placebo and ritonavir/placebo, through 
4days after the last dose of PF -07321332/placebo and ritonavir/placebo. If a participant cannot temporarily 
interrupt the prohibited medication during this period, they should be considered ineligible.   
Drug Class Specific Medication Clinical Comments 
Ombitasvir/Paritaprevir/Ritonavir 
and Dasabuvir
Sofosbuvir/Velpatasvir/VoxilaprevirRefer to the 
Ombitasvir/Paritaprevir/Ritonavir and 
Dasabuvir label for further information.
Refer to the 
Sofosbuvir/Velpatasvir/Voxilaprevir 
product label for further information.
Patients on ritonavir -containing HCV 
regimens should continue their treatment 
as indicated. Monitor for increased 
PAXLOVID or HCV drug adverse 
events with concomitant use.
HIV Antiretrovirals 
Protease Inhibitors 
Integrase Inhibitors Lopi[INVESTIGATOR_054], Amprenavir, Indinavir, 
Nelfinavir, Atazanavir, Darunavir, 
Fosamprenavir, Saquinavir, 
Tipranavir. 
Ritonavir or cobicistat containing 
combination products 
Elvitegravir Co-administration may increase HIV 
protease inhibitor concentrations. 
Risk of increased rate of adverse 
reactions. Appropriate doses of 
additional Ritonavir in combination with 
ritonavir -containing combination 
products w ith respect to safety and 
efficacy have not been established. 
Co-administration will increase 
Elvitegravir concentrations. 
Hormonal contraceptive Ethinyl Estradiol An additional, non -horm onal method of 
contraception should be considered.
Lipid low ering drugs 
(HMG -CoA Reductase 
Inhibitors) Atorvastatin (>20 mg daily), 
Rosuvastatin (>10 mg daily) 
Lomitapi[INVESTIGATOR_295383]-administration may increase 
concentration of Lomitapi[INVESTIGATOR_5328]. 

PF-[ADDRESS_1069133] dose of PF -07321332/placebo and ritonavir/placebo, through 
4days after the last dose of PF -07321332/placebo and ritonavir/placebo. If a participant cannot temporarily 
interrupt the prohibited medication during this period, they should be considered ineligible.   
Drug Class Specific Medication Clinical Comments 
Hypoglycemics Glipi[INVESTIGATOR_7130], Tolbutamide 
Repaglinide 
Saxagliptin (>2.5 mg daily) Potentially decrease glipi[INVESTIGATOR_778386]. 
Potentially increase Repaglinide 
concentrations.  
Co-administration may increase 
Saxagliptin concentration. 
Immunosuppressants Cyclosporine, Tacrolimus, 
Sirolimus, Everolimus Co-administration may increase 
immunosuppressant concentrations.  
Therapeutic concentration monitoring is 
recommended for immunosuppressants.
Long -Acting Beta -
Adrenoceptor Agonist Salmeterol The combination may result in increased 
concentrations of Salmeterol and 
increased risk of cardiovascular adverse 
events, including QT prolongation, 
palpi[INVESTIGATOR_778387]. 
Neuroleptic s Pi[INVESTIGATOR_778388]/ 
Hypnotics Midazolam (parenteral), 
Alprazolam, Bromazepam, 
Brotizolam, Clonazepam, 
Cloniprazepam, Delorazepam, 
Diazepam, Etizolam, Eszopi[INVESTIGATOR_11123], 
Halazepam, Lormetazepam, 
Nitrazepam, Nordiazpam, 
Quazepam, Suvorexant, 
Temazepam, Zaleplon, Zolpi[INVESTIGATOR_778389], Estazolam, 
Flurazepam, 
Zolpi[INVESTIGATOR_6730] (> 5mg daily) Risk of prolonged sedation, respi[INVESTIGATOR_41826], or hypnotic concentrations 
Co-administration with Ritonavir may 
increase dose of Clorazepate, Estazolam, 
and Flurazepam. 
Co-administration may increase 
zolpi[INVESTIGATOR_778390]  
a.Note: If a drug is not listed, it should not automatically be assumed it is safe to co -administer. 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 114Precautionary Medications
Medications m ay be used with caution and require oversight by [CONTACT_778426] -adm inistered 
with PF- 07321332/ritonavira
Drug Class Specific Medication Clinical Comments
Antidepressant Citalopram, Escitalopram, 
Sertraline, No data available
Co-administration may decrease Sertraline 
and Bupropi[INVESTIGATOR_577626].
Antihypertensive 
Angiotensin receptor 
blockers: Losartan, Valsartan Co-administration with Ritonavir increases 
the level/effect of Losartan by [CONTACT_295430]/intestinal enzyme CYP3A4 
metabolism. Ritonavir increases the 
level/effect of Valsartan by [CONTACT_295431]. To be used with caution. 
Antiparasitic: Atovaquone
QuinineCo-administration with Ritonavir may 
decrease the concentration of Atovaquone.
Co-administration with Ritonavir may 
decrease concentration of Quinine.
Antipsychotic: Haloperidol Co-administration with ritonavir increases 
the level/effect of Haloperidol by [CONTACT_295430]/intestinal CYP3A4 metabolism. 
Haloperidol and Ritonavir both increase 
QTc interval. To be used w ith caution. 
Bronchodilator: Theophylline Co-administration with Ritonavir may 
decrease Theophylline concentration.
Corticosteroids Fluticasone Ritonavir twice daily increases Fluticasone 
AUC [ADDRESS_1069134]
Integrase inhibitorsDelavirdine
Maraviroc
RaltegravirCo-administration may increase Ritonavir 
concentration.
Co-administration may increase Maraviroc 
concentration.
Raltegravir concentrations may be 
decreased.
Hypoglycemics Canagliflozin Co-administration may decrease
Canagliflozin concentration.
Narcotic and 
Treatment for Opi[INVESTIGATOR_778391]-administration may increase 
concentration of Tramadol.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 115Medications m ay be used with caution and require oversight by [CONTACT_778426] -adm inistered 
with PF- 07321332/ritonavira
Drug Class Specific Medication Clinical Comments
PDE -5 Inhibitors for 
treatment of erectile 
dysfunctionSildenafil –ED (m ax dose 25 mg 
every 48 hours)
Avanafil
Tadalafil (max dose 10 mg every 72 
hours)
Vardenafil (max dose 2.5 mg every 72 
hours)Risk of visual disturbances, hypotension, 
prolonged erection, and syncope
Steroids (systemic) Dexamethasone
PrednisoneCo-administration with ritonavir may 
increase dose of Dexamethasone and 
Prednisone and may increase the risk for 
development of systemic corticosteroid 
effects including Cushing’s syndrome and 
adrenal suppression.
Stimulant Methamphetamine Co-administration with Ritonavir may 
increase concentration of  
Methamphetamine.
a.Note: If a drug is not listed, it should not automatically be assumed it is safe to co -administer

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE].9. Appendix 9: Signs and Symptoms Consistent With COVID-19
Table 2. Signs and Symptoms Consistent With COVID - 19
Daily Sign and Symptom Collection53Exclusion 
Criterion #2Daily Signs and 
Symptom  
CollectionTargeted 
Symptoms For 
Analysis
Cough X X X
Shortness of breath or difficulty breathing X X X
Fever (documented temperature >38 ˚C [100.4˚F]) or 
subjective fever (eg, feeling feverish)X
Feeling feverish X X X
Chills or shivering X X X
Fatigue (low energy or tiredness) X X X
Muscle or body aches X X X
Diarrhea (loose or w atery stools) X X X
Nausea (feeling like you wanted to throw  up) X X X
Vom iting (throw  up) X X X
Headache X X X
Sore throat X X X
Stuffy or runny nose X X X
Loss of smell X X X
Loss of taste X X X

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE].10. Appendix 10: High -Risk Close Contact [CONTACT_778427] -risk close contact [CONTACT_778428] y of the following exposures without the consistent 
appropriate use of recommended personal protective equipment (eg, face mask)44:
Provided direct care for the index case
Had close direct ph ysical contact [CONTACT_497170]
Lived with the index case
Had close indoor contact (within 2 m), with or without direct phy sical contact, for at 
least 1 hour
Had direct contact [CONTACT_497171], including oral secretions, respi[INVESTIGATOR_477607], or stool .

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE].11. Appendix 11: Risk Factors Associated With Severe COVID -19 Il lness67
≥60 y ears of age
BMI >25
Current smoker (cigarette smoking within the pa st 30 day s) and history  of at least 
100lifetime cigarettes
Immunosuppressive disease (eg, bone marrow or organ transplantation or primary  
immune deficiencies) OR prolonged use of immune- weakening medications:
oHas received corticosteroids equivalent to prednisone ≥20mg dail y for at least 
14 consecutive day s within 30 day s prior to study  entry
oHas received treatment with biologics (eg, infliximab, ustekinumab), 
immunomodulators (eg, methotrexate, 6MP, azathioprine), or cancer 
chemotherap y within 90 day s prior to study  entry ’
oHIV infection with CD4 cell count <200 mm3and a viral load less than 
400copi[INVESTIGATOR_014]/mL .
Chronic lung disease (if asthma, requires daily  prescribed therapy )
Known diagnosis of h ypertens ion
CVD, defined as history  of any  of the following: my ocardial infarction, stroke, TIA, 
HF, angina with prescribed nitrogl ycerin, CABG, PCI , carotid endarterectomy , and 
aortic b ypass
Type 1 or Ty pe 2 diabetes mellitus
CKD 
Sickle cell disease
Neurodevelopmental disorders (eg, cerebral pals y, Down's s yndrome) or other 
conditions that confer medical complexity  (eg, genetic or metabolic s yndromes and 
severe congenital anomalies);
Active cancer, other than localized skin cancer, including those requiring treat ment as 
long as the treatment is not among the prohibited medications that must be 
administered/continued during the stud y period;
Medical -related technological dependence (eg, CPAP [not related to COVID- 19]).

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE].12. Appendix 12: Country Specific Requireme nts
10.12.1. Japan
A Protocol Administrative Change Letter was issued on 22 July 2021 to provide Japan 
country  specific guidance regarding Exclusion Criterion #5 .
Exclusion Criterion #5: Known HIV infection with a viral load >400 copi[INVESTIGATOR_014]/mL  or taking 
prohibited med ications for HIV treatment (from known medical history within past 6 months 
of the screening visit).
If HIV infection is known by  [CONTACT_295432] (if any ), the 
investigators must consult with the patient’s HIV treatment specialist to confirm that the HIV 
RNA level has been monitored at an appropriate frequency  and the HIV RNA level has been 
≤400 copi[INVESTIGATOR_014]/mL  during the past 6 months before the screening visit in order to assess the 
study  eligibility  of that patient.
Rationale: There is a risk for patients with uncontrolled HIV to develop resistance to 
ritonavir which is being administered with PF -07321332. According to the HIV treatment 
guideline in Japan, even if there is an occasional increase in the amount of HIV RNA in the 
blood to about 20 -500 copi[INVESTIGATOR_014]/mL , the same treatment may  be continued. The guideline 
recommends a resistance test when HIV RNA levels exceed 500 copi[INVESTIGATOR_014]/mL.
10.12.2. Bulgaria
A Protocol Administrative Change Letter was issued on [ADDRESS_1069135] 2021 to provide Bulgaria 
country  specifi c guidance regarding exclusion criteria 3 and 5 on participants with known 
hepatitis B or C infection (chronic or active) or poorly controlled HIV (viral load >400 
copi[INVESTIGATOR_014]/mL  within the last 6 months).
Per guidance from Bulgarian regulatory  authorities, hep atitis B and C and HIV testing must 
be performed for all participants being evaluated for participation in Study  C4671006 to 
objectively  confirm that participants do not have active or chronic hepatitis B or C or poorl y 
controlled HIV infection as specifie d in protocol exclusion criteria 3 and 5. Required viral 
testing should be performed at the local laboratory and results are to be retained in participant 
source documents. If results for the required testing are not available within the protocol 
specified Screening period (24 hours prior to randomization), the participant will not be 
eligible to participate in the study .
Revised note on Clinical Laboratory  Tests from section 1.3 (additions in bold) :
Local testing for hepatitis B, hepatitis C and HIV is req uired to confirm 
participant eligibility per exclusion criteria 3 and 5.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE].12.3. Ukraine
A Protocol Administrative Change Letter was issued on 22 Dec 2021 to provide Ukraine 
country  specific guidance regarding nasal swab collection.
As per Ministry  of Health of Ukraine Order # [ADDRESS_1069136] diagnostic tests for COVID- 19 performed by  a healthcare professional. The change 
being made in this letter is to shift from nasal swab self collection b y the pa rticipants to nasal 
swab collection performed by a healthcare professional .
Revised note on Nasal Swab from section 1.3 (deletions in strikethrough)
At baseline, a nasal swab will be selfcollected by  [CONTACT_778404] -
PCR status (+ or -); this test will not be used to determine study  eligibility . The 
sample will be collected under observation by  [CONTACT_778429]. Thereafter, nasal swabs will be selfcollected by [CONTACT_778430] , preferabl y in the morning. 
Nasal swabs will be selfcollected from Day  1 to 14 including day s when a study  visit 
occurs (**including at unplanned visits).
Revised first paragraph from section [IP_ADDRESS] (deletions in strikethrough, additions in bold): 
The first nasal swab will be self collected b y the participant under observation by [CONTACT_778431]. Thereafter, Nasal swabs will be self collected by  a 
healthcare professional the participant at about the same time each day , preferabl y in the 
morning. If an in -person visit occurs on the same day  as self collection of the nasal swab, the 
nasal swab self -collection should be done prior to the visit. 
Additional swabs may  be required at the visit on day s for which an in -person visit occurs (eg, 
COVID -19 Signs/S ymptoms Onset visit). Participants A healthcare professional should 
collect conduct the nasal swab self-collection for Viral Load Assessment by [CONTACT_778432] s described in the SoA, including those for which an in -
person visit is scheduled.
It is noted that the PACL dated 14 December 2021 is not applicable in Ukraine .

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE].13. Appendix 13: Glossary of Terms
Term Definition68-[ADDRESS_1069137] Someone who has been within 6 feet (1.8 meters) of an infected 
person (laboratory -confirmed or a clinicall y compatible illness) 
for a cumulative total of 15 minutes or more over a 24 -hour 
period (for example, 3 individual 5 -minute exposures for a total 
of 15 minutes in one day ). 
Contact [CONTACT_778433] a source of an infection; a person who has been 
exposed
Confirmed COVID -[ADDRESS_1069138] of their 
community  or population
Household A group of people (two or more) living in the same residence
Including, but not limited to:
Two or more people living together in a domestic 
residence (residential institutions, such as boarding 
schools, dormitories, hotels or prisons will be excluded) 
and 
A dwelling or gr oup of dwellings with a shared kitchen 
or common opening onto a shared household space
Household contact [CONTACT_778434] (or other 
closed setting) as a confirmed COVID -[ADDRESS_1069139] not been so exposed 
to prevent the possible spread of the communicable disease. 
Quarantine may  be voluntary  or compelled by  [CONTACT_1032], state, or 
local public health order.
Secondary  attack rate A measure of the frequency  of new cases of a disease among 
the contacts of known patients
Source Case The case or instance of a patient responsible for transmitting 
infection to others; the instance of a patient who gives rise to an 
outbreak or epi[INVESTIGATOR_778392]-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE].14. Appendix 14: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
3CL 3C-like protein
6MP mercaptopurine
Abs absolute
AE adverse event
AESI adverse events of special interest
ALT alanine aminotransferase
ANCOVA analysis of covariance
APTT activated partial thromboplastin time
ARDS acute respi[INVESTIGATOR_273471] -time curve
AV atrioventricular
-hCG beta-human chorionic gonadotropin
BID twice a day
BMI body  mass index
bpm beats per minute
BUN blood urea nitrogen
CABG coronary  artery  by[CONTACT_295434]5 chemokine receptor t ype 5
CD4 cluster of differentiation 4
CDC [LOCATION_002] Centers for Disease Control and Prevention
CFR Code of Federal Regulations
CHW Cui, Hung, and Wang
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD chronic kidney  disease
CKD -EPI [INVESTIGATOR_295397] 2 carbon dioxide (bicarbonate)
CONSORT Consolidated Standards of Reporting Trials
COVID -[ADDRESS_1069140] acting antivirals
DAIDS Division of AIDS
DDI drug-drug interaction 
DILI drug-induced liver injury
DMC Data Monitoring Committee
DNA deox yribonucleic acid
dNHBE differentiated normal human bronchial epi[INVESTIGATOR_295398] 90 concentration required for 90% effect
ECC emergency  contact [CONTACT_295435] d ysfunction
EDB exposure during breastfeeding
E-DMC external data monitoring committee
EDP exposure during pregnancy
eGFR epi[INVESTIGATOR_778393]-5D EuroQol -[ADDRESS_1069141]-in-human
FSH follicle -stimulating hormone
fu fraction of unbound drug in serum or plasma
GCP Good Clinical Practice
GEE Generalized estimating equation
GGT gamma -glutamy l transferase
GLP Good Laboratory  Practice
Ha alternative h ypothesis
HCoV human coronavirus
HCP health care professional; health care provider
HCV hepatitis C virus
HDPE high-densit y pol yethylene

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 125Abbreviation Term
HF heart failure
HIV human immunodeficiency virus
H0 Null hy pothesis
HR heart rate
HRT hormone replacement therap y
hsCRP high-sensitivity  C-reactive protein
HTA health technologies assessment
IB Investigator’s Brochure
ICD informed consent document
ICH International Council for Harmonisation
ICU intensive care unit
ID identification
IMP investigational medicinal product
IND Investigational New Drug
INR international normalized ratio
IP manual investigational product manual
IPAL Investigational Product Accountability  Log
IRB Institutional Review Board
IRT Interactive Response Technology
IV intravenous
IWR interactive Web -based response
LDH lactate deh ydrogenase
LFT liver function test
mAb monoclonal antibody
MAD multiple ascending dose
mITT modified intent -to-treat
MMRM mixed -effect model repeated measure
MRC -[ADDRESS_1069142]
NP nasophary ngeal
PACL protocol administrative change letter
PCI percutaneous coronary  intervention
PDE -5 phosphodiesterase
PK pharmacokinetic(s)
PP Per-protocol
PRO patient -reported outcome
PT prothrombin time

PF-[ADDRESS_1069143]
QTc corrected QT
QTcF corrected QT using Fridericia’s formula
QTL quality  tolerance limit
RBC red blood cell
RNA ribonucleic acid
RSV respi[INVESTIGATOR_214321]-PCR reverse transcription polymerase chain reaction
RT-qPCR real-time quantitative polymerase chain reaction
SAD single ascending dose
SAE serious adverse event
SAP Statistical Analy sis Plan
SARS -CoV -[ADDRESS_1069144] upper limit of normal
US [LOCATION_002]
USPI [INVESTIGATOR_185578] I nformation; [LOCATION_002] Package 
Insert
VAS visual analog scale
WBC white blood cell
WHO World Health Organization
WOCBP woman/women of childbearing potential
WPAI Work Productivity  and Activity  Impairment Questionnaire
WPAI -GH Work Productivity  and Activity  Impairment Questionnaire -General
Health

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE].15. Appendix 14: Protocol Amendment History
Amendment 1 ([ADDRESS_1069145] 2021)
The Protocol Amendment Summary  of Changes Table for the current amendment is located 
directly  before the table of contents (TOC).  The protocol amendment summary  of changes 
tables for past amendment(s) can be found below:
Overall Rationale for the Amendment 1: 
The protocol was amended to modify  the eligibility  criteria for the study  to exclude Rapid 
Antigen Test positive participants, modify  the primary  anal ysis set, and provide clearer 
guidance for assessment of participants who develop sy mptomatic SARS -CoV -2 infection. 
Section # and Name [CONTACT_23688]
3. Objectives, Endpoints, 
and Estimands
9. Statistical 
ConsiderationsPrimary analysis set limited to 
participants who have a negative 
RT-PCR result at baseline.
Primary and secondary 
estimand/endpoints adapted to 
include adults who have a 
negative RT -PCR result at 
baseline, as applicable.
Additional detail provided in 
description of primary and key 
secondary analyses including 
intercurrent event.By [CONTACT_243124] a 
positive RT -PCR result at baseline 
from the primary analysis set, this 
analysis more accurately reflects 
postexposure prophylaxis.
Addition of intercurrent events 
provides greater clarity to the 
analysis of primary and key 
secondary endpoints.
1. Protocol Summary
4.[ADDRESS_1069146]. 
1. Protocol Summary
4.1. Overall Design
[IP_ADDRESS]. Data 
Monitoring CommitteeEnrollment pause for unblinded 
E-DMC safety data review of 
sentinel cohort
E-DMC meeting frequency 
specified.Enrollment pause allows time for 
E-DMC review of sentinel cohort 
safety data prior to further 
enrollment. 
E-DMC meeting frequency 
provides greater clarity in the 
protocol. 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 128Section # and Name [CONTACT_23688]
1. Protocol Summary
4.1. Overall Design
[IP_ADDRESS]. Data 
Monitoring Committee
9.4. Interim AnalysesFutility assessment incorporated 
into interim analysis.
More details on interim analysis 
including stoppi[INVESTIGATOR_778394] E -DMC to discontinue one or 
both active treatment groups. 
1.3 Schedule of 
Activities
4.2. Overall Design
8.1.2. Daily Signs and 
Symptoms of COVID -19
8.1.3. COVID -19 Related 
Medical Visit Details
8.2.4. Vital SignsAddition of COVID -19 Signs/ 
Symptoms Onset visit, including 
triggers for the visit and 
assessments to be performed.Addition of this visit provides 
guidance for assessment of 
participants who develop 
COVID -[ADDRESS_1069147] will 
reduce enrollment of participants 
with positive baseline RT -PCR 
results. 
10.9. Signs and 
Symptoms Attributable 
to COVID -19Addition of loss of taste and loss 
of smell to exclusionary 
symptoms and to symptoms that 
will be assessed in efficacy 
analyses.Loss of taste/smell is a frequent 
first symptom associated with 
SARS -CoV -[ADDRESS_1069148] of prohibited medications 
for study entry.Increases focus of eligibility on 
postexposure prophylaxis.
9.1.2. Multiplicity 
AdjustmentClarification that if one of the 
PF-07321332/ritonavir groups is 
discontinued, sequential testing Increase clarity on multiplicity 
adjustment if one of the 

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 129Section # and Name [CONTACT_778438]-07321332/ritonavir group in 
the order of the primary endpoint 
and key secondary endpoint.PF-07321332/ritonavir groups is 
discontinued.
10.12.2. Japan Japan country -specific 
requirement for consultation on 
HIV RNA monitoring.Inclusion of this consultation 
incorporates country- specific 
changes to the global protocol. 
6.[ADDRESS_1069149] of care.Allows identification of other 
respi[INVESTIGATOR_778395] -CoV -2
1.3. Schedule of 
Activities
8.6 Biomarkers
[IP_ADDRESS]. Viral Load 
AssessmentsRemoval of NP swabs.
Instruction that first nasal swab 
is to be self collected by 
[CONTACT_778435].NP swabs removed to use a 
consistent swab source (nasal).
First nasal swab will be 
selfcollected by [CONTACT_778436].
[IP_ADDRESS]. Viral Load 
AssessmentsSARS -CoV -2 positive nasal 
swab samples will undergo 
additional testing.Increases understanding of 
SARS -CoV -2 kinetics in study 
participants.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page 130Section # and Name [CONTACT_23688]
1.3. Schedule of 
ActivitiesUpdates to description of visit 
conditions in footnotes.Increases clarity for study conduct.
1.[ADDRESS_1069150].
8.2.2. Height and Weight Height may be self reporte d. Consistency with other C467 
Phase 2/3 studies.
Protocol Title
1. Protocol Summary
2. Introduction
3. Objectives, Endpoints, 
and EstimandsIndex cases described as 
individuals with “symptomatic 
COVID -19”.Document clarity and consistency
8. Study Assessments 
and ProceduresCorrect total blood sampling 
volume.Document clarity and consistency.
10.4.3. Woman of 
Childbearing PotentialFSH is used to confirm 
postmenopausal state in women 
under 50 years of age.Document clarity and consistency.
Title Page Phase 3 was updated to Phase 
2/3.Document clarity and consistency.
Throughout Editorial changes and correction 
of typographical errors.Document clarity and consistency.

PF-[ADDRESS_1069151] sheet for healthcare providers emergency  use 
authorization of PaxlovidTM. Report Number: December 2021. Available from: 
https://www.fda.gov/media/155050/download. Accessed on: 24 January  2022.
2. O'Brien MP, Forleo -Neto E, Musser BJ, et al. Subcutaneous R EGEN -COV Antibody  
Combination to Prevent Covid- 19. N Engl J Med. 2021;385(13):1184 -95.
3. World Health Organization. 2019- nCoV outbreak is an emergency  of international 
concern. 31 Jan 2020. Available from: https://www.euro.who.int/en/health -
topi[INVESTIGATOR_1102]/health- emergencies/coronavirus -covid-19/news/news/2020/01/2019- ncov -
outbreak- is-an-emergency -of-international -concern. Accessed on: 22 March 2020.
4. World Health Organization. WHO Situation Report 51 Coronavirus disease 2019 
(COVID -19). 11 March 2020. Available from: https://www.who.int/docs/default -
source/coronaviruse/situation -reports/20200311 -sitrep-51- covid-
19.pdf?sfvrsn=1ba62e57_10. Accessed on: [ADDRESS_1069152] by  [CONTACT_214363] S ystems 
Science and Engineerin g (CSSE) at Johns Hopkins University  (JHU). Available from: 
https://coronavirus.jhu.edu/map.html. Accessed on: 12 Jan 2022.
6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the 
Coronavirus Disease 2019 (COVID -19) Outbreak in China: Summa ry of a Report of 
[ZIP_CODE] Cases From the Chinese Center for Disease Control and Prevention. JAMA. 
2020;323(13):1239 -42.
7. Dochert y AB, Harrison EM, Green CA, et al. Features of 20 133 [LOCATION_006] patients in 
hospi[INVESTIGATOR_61010]- 19 using the ISARIC WHO Clinical Chara cterisation Protocol: 
prospective observational cohort study . BMJ. 2020;369:m1985.
8. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, 
Comorbidities, and Outcomes Among 5700 Patients Hospi[INVESTIGATOR_45086] -19 in 
the [LOCATION_001] City  Area. JAMA. 2020;323(20):2052 - 59.
9. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with 
coronavirus disease 2019: retrospective stud y. BMJ. 2020;368:m1091.
10. Cummings MJ, Baldwin MR, Abrams D, et al. Epi[INVESTIGATOR_623] , clinica l course, and 
outcomes of criticall y ill adults with COVID- 19 in [LOCATION_001] Cit y: a prospective 
cohort study . Lancet. 2020;395([ZIP_CODE]):1763 -70.
11. Mehta P, McAuley  DF, Brown M, et al. COVID -19: consider cy tokine storm 
syndromes and immunosuppression. Lancet. 2020;395([ZIP_CODE]):1033-34.
12. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospi[INVESTIGATOR_45077] 
2019 Novel Coronavirus -Infected Pneumonia in Wuhan, China. JAMA. 
2020;323(11):1061 -69.
13. Cao B, Wang Y, Wen D, et al. A Trial of Lopi[INVESTIGATOR_054] -Ritonavir in Adults Hospi[INVESTIGATOR_95264] -19. N Engl J Med. 2020;382(19):1787 -99.
14. Cavalcanti AB, Zampi[INVESTIGATOR_295401], Rosa RG, et al. Hy droxy chloroquine with or without 
Azithromy cin in Mild -to-Moderate Covid -19. N Engl J Med. 2020;383(21):2041 -52.
15. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of Hy droxychloroquine Usage 
in [LOCATION_002] Veterans Hospi[INVESTIGATOR_21391]
-19. Med (N Y). 2020;1(1):114-
[ADDRESS_1069153] treatment for COVID-19. 
May 2020. Available from: https://www.fda.gov/news -events/press -
announcements/fda
-approves- first-treatment -covid -
19?utm_medium=email&utm_source=govdelivery. Accessed on: 29 Jun 2021.
17. Beigel JH, Tomashek KM, Dodd L E, et al. Remdesivir for the Treatment of Covi d-19 
-
Final Report. N Engl J Med. 2020;383(19):1813-26.
18. Spi[INVESTIGATOR_95265], Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on 
Clinical Status at 11 Days in Patients With Moderate COVID -19: A Randomized 
Clinical Trial. JAMA. 2020;324(11): 1048-57.
19.
Consortium WHOST, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid -19 
-Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):[ADDRESS_1069154] 
neglected and emerging RNA viruses. Antiviral Res. 2018;153:85-94.
21. Santos J, Brierley  S, Gandhi MJ, et al. Repurposing Therapeutics for Potential 
Treatment of SARS -CoV -2: A Review. Viruses. 2020;12(7).
22. Joshi S, Parkar J, Ansari A, et al. Role of favipi[INVESTIGATOR_295402] -19. 
Int J I nfect Dis. 2021;102:501 -08.
23. Li Q, Guan X, Wu P, et al. Early  Transmission Dynamics in Wuhan, China, of Novel 
Coronavirus -Infected Pneumonia. N Engl J Med. 2020;382(13):1199-207.
24. Bi Q, Wu Y, Mei S, et al. Epi[INVESTIGATOR_778396] D-19 in 391 cases 
and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study . 
Lancet Infect Dis. 2020;20(8):911 -19.
25. World Health Organization. Report of the WHO- China Joint Mission on Cor onavirus 
Disease 2019 (COVID -19). 2020. Available from: https://www.who.int/docs/default -
source/coronaviruse/who -china -joint-mission -on-covid - 19- final-report.pdf. Accessed 
on: 10 Jun 2021.
26. Zhao S, Lin Q, Ran J, et al. Preliminary  estimation of the basi c reproduction number 
of novel coronavirus (2019
-nCoV) in China, from 2019 to 2020: A data -driven 
analysis in the earl y phase of the outbreak. Int J I nfect Dis. 2020;92:214- 17.
27. World Health Organization. Strengthening preparedness for COVID -19 in citie s and 
urban settings. 2020. Available from: 
https://www.who.int/publications/i/item/strengthening-preparedness- for-covid - 19- in-
cities
-and-urban -settings. Accessed on: 10 Jun 2021.
28. Hellewell J, Abbott S, Gimma A, et al. Feasibility of controlling COVID -19 
outbreaks b y isolation of cases and contacts. Lancet Glob Health. 2020;8(4):e488 -
e96.
29. He X, Lau EHY, Wu P, et al. Temporal d ynamics in viral shedding and 
transmissibility of COVID -19. Nat Med. 2020;26(5):672-75.
30. Soleimanpour S, Yaghoubi A. COVID -19 vaccine: where are we now and where 
should we go? Expert Rev Vaccines. 2021;20(1):23-44.
31. US Food and Drug Administration.  COVI D-19 Vaccines. Available from: 
https://www.fda.gov/emergency -preparedness- and-response/coronavirus- disease -
2019- covid -19/covid-19- vaccines. Accessed on: [ADDRESS_1069155] COVID -19 Vaccine Development and Antibody  Treatment. Pathogens. 
2020;9(5).
33. Mahase E. Covid -19: What new variants are emerging and how are they  being 
investigated? 2021;372:n158.
34. [LOCATION_006] Health Security  Agency . SARS -CoV -2 variants of concern and variants under 
investigation in England. 10 December 2021. Available from: 
https://assets.publishing.service.gov.uk/government/uploads/sy stem/uploads/attachme
nt_data/file/1042367/technical_briefing -
31-10- december -2021.pdf. Accessed on: 20 
January  2022.
35. Planas D, Saunders N, Maes P, et al. Considerable escape of SARS -CoV -2 Omicron 
to antibody  neutralization. Nature. 2021;10.1038 /s41586 -
021-[ZIP_CODE]- z.
36. World Health Organization. WHO global influenza preparedness plan : the role of 
WHO and recommendations for national measures before and during pandemics. 
2005. Available from: https://apps.who.int/iris/handle/[ZIP_CODE]/[ZIP_CODE]. Accessed on: 29 
Jun 2021.
37. Smit M, Marinosci A, Nicoletti GJ, et al. Efficacy  of pragmatic same -day ring 
prophy laxis for adult individuals exposed to SARS -CoV -2 in Switzerland (COPEP): 
protocol of an open -
label cluster randomised trial. BMJ Open. 2020;10(11):e040110.
38. US Food and Drug Administration. US Food and Drug Administration (2021). Fact 
sheet for health care providers emergency  use authorization (EUA) of Regen- Cov 
(casirivimab and imdevimab). Report Number: 04 June 2021. Available from: 
https://www.fd a.gov/media/145611/download. Accessed on: [ADDRESS_1069156] 2021.
39. Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) 
structure: basis for design of anti -SARS drugs. Science. 2003;300(5626):1763 -7.
40. [COMPANY_007]. I nvestigator's Brochure PF-07321332. June 2021. Version 3.0. Data on file.
41. NORVI R (ritonavir). US Prescription Information (USPI ); Oct 2020, North Chicago, 
IL, [LOCATION_003]: [COMPANY_013] Inc. Available from: 
https://www.accessdata.fda.gov/spl/data/551acd76 -c57f-3546-038d-
c36559b90735/551acd 76
-c57f-3546-038d- c36559b90735.xml. Accessed on: 29 Jun 
2021.
42.
US Food and Drug Administration. Paxlovid (nirmatrelvir tablets and ritonavir 
tablets, co-packaged for oral use). Letter of Authorization. 23 December 2021. 
Available from: https://www.fda.g ov/media/155049/download. Accessed on: 20 
January  2022.
43. US Food and Drug Administration. Molnupi[INVESTIGATOR_42654]. Letter of Authorization. 23 
December 2021. Available from: https://www.fda.gov/media/155053/download. 
Accessed on: [ADDRESS_1069157] SARS -CoV -2 in 
close contacts of confirmed COVID -19 cases (CORI PREV): study  protocol for a 
cluster -randomized trial. Trials. 2021;22(1):224.
45. Lilly 's neutralizing antibody  bamlanivimab (LY -CoV555) pre vented COVID- 19 at 
nursing homes in the BLAZE -2 trial, reducing risk by  [CONTACT_8622] 80 percent for residents 
[press release]. 21 January  2021.

PF-07321332
Protocol C4671006
Final Protocol Amendment 2, 25 January 2022
PFIZER CONFIDENTIAL
Page [ZIP_CODE]. COVID -19 Study  Assessing the Efficacy  and Safety  of Anti -Spi[INVESTIGATOR_778397] -2 
Monoclonal Antibodies for Prevention of SARS CoV -2 Infection As ymptomatic in 
Health y Adults and Adolescents Who Are Household Contacts to an I ndividual With 
a Positive SARS -CoV -2 RT -PCR Assay . Available from: 
https://clinicaltrials.gov/ct2/show/study /[STUDY_ID_REMOVED]. Accessed on: 29 Jun 2021.
47. Mitja O, Corbacho- Monne M, Ubals M, et al. A Cluster -Randomized Trial of 
Hydroxy chloroquine for Prevention of Covid- 19. N Engl J Med. 2021;384(5):[ADDRESS_1069158], Pullen MF, Bangdiwala AS, et al. A Randomized Trial of 
Hydroxy chloroquine as Postexposur e Prophy laxis for Covid -19. N Engl J Med. 
2020;383(6):517 -25.
49. Barnabas RV, Brown ER, Bershtey n A, et al. Hy droxy chloroquine as Postexposure 
Prophy laxis to Prevent Severe Acute Respi[INVESTIGATOR_349360] 2 I nfection : 
A Randomized Trial. Ann I ntern Med. 2021;174(3):[ADDRESS_1069159] Pharmacol. 
2021;10(1):18 -29.
51. Lepen L, Blagus R, Veluscek M, et al. Five- Day vs 10 -Day Postexposure 
Chemoprophy laxis With Oseltamivir to Prevent Hospi[INVESTIGATOR_778398]: 
A Noninferiorit y Randomized Open -Label Study. Open Forum Infect Dis. 
2020;7(8):ofaa240.
52. Levey  AS, Stevens LA, Schmid CH, et al. A new equation to estimat e glomerular 
filtration rate. Ann Intern Med. 2009;150(9):604- 12.
53. US Food and Drug Administration. Assessing COVID -19-Related Sy mptoms in 
Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological 
Products for COVID -19 Preventi on or Treatment. 2020. Available from: 
https://www.fda.gov/regulatory -information/search -fda-guidance -
documents/assessing -covid -
19-related -symptoms -outpatient -adult -and-adolescent -
subjects -clinical -trials
-drugs. Accessed on: 25 Mar 2021.
54. US Bureau of Labor Statistics.  Effects of COVID- 19 Pandemic on Productivity  and 
Costs Statistics. Available from: https://www.bls.gov/covid19/effects-of- covid - 19-
pandemic -
on-productivity -and-costs -statistics.htm. Accessed on: 08 Jun 2021.
55. Reilly  MC, Zbrozek AS, Duk
es EM. The validit y and reproducibility  of a work 
productivity  and activity  impairment instrument. Pharmacoeconomics. 
1993;4(5):353 -65.
56. Rabin R, Gudex C, Selai C, et al. From translation to version management: a history  
and review of methods for the cu ltural adaptation of the EuroQol five -dimensional 
questionnaire. Value Health. 2014;17(1):70 -6.
57. van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ -5D- 5L: mappi[INVESTIGATOR_74046] -5D- 5L to EQ -5D- 3L value sets. Value Health. 2012;15(5):708 -15.
58. Ramos -Goni JM, Pi[INVESTIGATOR_1946] -Prades J L, Oppe M, et al. Valuation and Modeling of EQ -5D-
5L Health States Using a Hy brid Approach. Med Care. 2017;55(7):e51- e58.
59. Yang Y, Brazier J, L ongworth L . EQ-5D in skin conditions: an assessment of validity  
and responsiveness. Eur J Health Econ. 2015;16(9):[ADDRESS_1069160] AS, Golicki D, et al. Measurement properties of the EQ-5D- 5L 
compared to the EQ -5D- 3L across eight patient groups: a multi -country  study . Qual 
Life Res. 2013;22(7):1717-27.
61. Herdman M, Gud ex C, Lloy d A, et al. Development and preliminary  testing of the 
new five -level version of EQ -5D (EQ -5D- 5L). Qual L ife Res. 2011;20(10):1727 -36.
62. Agborsangay a CB, Lahtinen M, Cooke T, et al. Comparing the EQ -5D 3L and 5L : 
measurement properties and asso ciation with chronic conditions and multimorbidity  
in the general population. Health Qual Life Outcomes. 2014;12:74.
63. EuroQol G. EuroQol --a new facility  for the measurement of health- related quality  of 
life. Health Policy . 1990;16(3):199-208.
64. U.S. D epartment of Health and Human Services NIoH, National Institute of Allergy  
and Infectious Diseases, Division of AIDS,. Division of AIDS (DAIDS) Table for 
Grading the Severity  of Adult and Pediatric Adverse Events, Corrected Version 2.1. 
July 2017. Availabl e from: 
https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf. Accessed 
on: 10 Jun 2021.
65. Benjamini Y, & Hochberg, Y. Controlling the false discovery rate: a practical and 
powerful approach to multiple testing. . Journal of the Roy al Statistical Society . 
1995;57:289 –300.
66. Cui L , Hung HM, Wang SJ. Modification of sample size in group sequential clinical 
trials. Biometrics. 1999;55(3):853
-7.
67. ERA -EDTA Council EWG, Ortiz A.,  et al. Chronic kidney  disease is a key  risk 
factor for severe COVID -19: a call to action b y the ERA -EDTA. Nephrology  Dial ysis 
Transplantation. 2020;36:87-94.
68. Centers for Disease Control and Prevention. Appendix A -glossary  of key  terms. 
2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/php/c ontact -
tracing/contact -tracing -plan/appendix.html#contact. Accessed on: [ADDRESS_1069161] Edition An I ntroduction to Applied Epi[INVESTIGATOR_778399]. Glossary . Available from: 
https://www.cdc.gov/csels/dsepd/ss1978/glossary .html. Accessed on: 28 Jun 2021.
70.
World Health Organization. Household transmission investigation protocol for 2019 -
novel coronavirus (COVID- 19) infection. Epi[INVESTIGATOR_778400]. 2020. Available 
from: https://www.who.int/publications/i/item/household- transmission- investigation -
protocol -for-2019 -novel -coronavirus -(2019 -ncov) -infection. Accessed on: 29 Jun 
2021.

'RFXPHQW $SSURYDO 5HFRUG
'RFXPHQW 1DPH	

 


  
'RFXPHQW 7LWOH	

 


  
6LJQHG %\ 'DWH*07 6LJQLQJ &DSDFLW\

 	  
! " #
$

 	 (  " #
$[COMPANY_003]
[COMPANY_003]